Organic Pharm. Chemistry III

Lecture 5
19th March 2023
10:30-12:30

AlNoor University College
Pharmacy Department
2nd Course/4th Class
2022/2023
You are capable of more than you know.
Objectives:
1. Understand the chemistry of drug with respect to their biological activity.
2. Know the Importance of SAR of Drugs
3. Know the metabolism, Adverse Effect and therapeutic value of drugs.

Learning Outcomes:
1. Students will Learn about the structures and Medicinal uses of Drugs.
2. Students will learn about relation of structure with its activity.
AMINOGLYCOSIDES

INTRODUCTION
- Include streptomycin, neomycin, kanamycin, amikacin, gentamicin, tobramycin, sisomicin, netilmicin, and others
- Widely in combination with a β-lactam antibiotic – serious infections with gram-negative bacteria
  – combination with vancomycin gram-positive endocarditis
- Treatment of Tuberculosis.

Mechanism of Action
- Irreversible inhibitors of protein synthesis on either of the ways – interference with the initiation complex of peptide formation – misreading of mRNA - incorporation of incorrect amino acids into the peptide and results in a nonfunctional or toxic protein – breakup of polysomes into nonfunctional monosomes

Mechanism of resistance
Production of a transferase - inactivates the aminoglycoside
- Impaired entry of aminoglycoside into the cell.
- Receptor protein on the 30S ribosomal subunit may be deleted or altered as a result of a mutation.
Physical and Chemical Properties

Aminoglycosides have a hexose ring, either streptidine (in streptomycin) or 2-deoxystreptamine (in other aminoglycosides), to which various amino sugars are attached by glycosidic linkages (Figures 1 and 2). They are water-soluble, stable in solution, and more active at alkaline than at acid pH.
FIGURE 2 Structures of several important aminoglycoside antibiotics. Ring II is 2-deoxystreptamine. The resemblance between kanamycin and amikacin and between gentamicin, netilmicin, and tobramycin can be seen. The circled numerals on the kanamycin molecule indicate points of attack of plasmid-mediated bacterial transferase enzymes that can inactivate this drug. ①, ②, and ③, acetyltransferase; ④, phosphotransferase; ⑤, adenylyltransferase. Amikacin is resistant to modification at ②, ③, ④, and ⑤.
CLINICAL USES

Mycobacterial Infections
– second-line agent for treatment of tuberculosis
– 0.5–1 g/d - intramuscularly or intravenously
– combination with other agents to prevent emergence of resistance

• Nontuberculous Infections
– plague, tularemia, and sometimes brucellosis: 1 g/d i/m in combination with an oral tetracycline.
– Combination with Penicillin
• enterococcal endocarditis
• 2-week therapy of viridans streptococcal endocarditis.
• enterococcal infections

ADVERSE REACTIONS

• Fever, skin rashes, and other allergic manifestations – hypersensitivity (prolonged course of treatment)
• Pain at the injection site
• Disturbance of vestibular function (irreversible) — vertigo and loss of balance - proportion to the Age of the patient,
– Blood levels of the drug
– Duration of administration
• Pregnancy: deafness in the newborn – relatively Contraindicated
**CLINICAL USE**

- **Topical Administration**
  - Solutions containing 1–5 mg/mL – infected surfaces or injected into joints, the pleural cavity, tissue spaces, or abscess cavities.
  - limited to 15 mg/kg/d – **higher doses may be absorbed to produce systemic toxicity.**
  - neomycin-polymyxin-bacitracin combination: applied to infected skin lesions or in the nares for suppression of staphylococci.

- **Oral Administration**
  - Preparation for **elective bowel surgery**: 1 g of neomycin with 1 g of erythromycin base is given orally every 6–8 hours for 1–2 days combined.
  - Reduces the aerobic bowel flora with little effect on anaerobes.
  - Hepatic encephalopathy: coliform flora can be suppressed by giving 1 g every 6–8 hours.
It is convenient to discuss sequentially aminoglycoside SARs in terms of **substituents in rings I, II, and III**.

**Ring I** is crucially important for characteristic broad spectrum antibacterial activity, and it is the primary target for bacterial inactivating enzymes. Amino functions at 6` and 2` are particularly important as kanamycin B (6`-amino, 2`-amino) is more active than kanamycin A (6`-amino, 2`-hydroxyl), which in turn is more active than kanamycin C (6`-hydroxyl, 2`-amino).

**Methylation** at either the 6`-carbon or the 6`-amino positions does not lower appreciably antibacterial activity and confers resistance to enzymatic acetylation of the 6`-amino group.

**Removal of the 3`-hydroxyl or the 4`-hydroxyl group or both in the kanamycins (e.g., 3`,4`-dideoxykanamycin B or dibekacin)** does not reduce antibacterial potency. The **gentamicins** also lack oxygen functions at these positions, as do sisomicin and netilmicin, which also have a 4`5`-dideoxykanamycin B or dibekacin) does not reduce antibacterial potency.
None of these derivatives is inactivated by phosphotransferase enzymes that phosphorylate the 3 hydroxyl group.

Evidently, the 3`-phosphorylated derivatives have very low affinity for aminoglycoside-binding sites in bacterial ribosomes.

**Ring II**

Few modifications of ring II (deoxystreptamine) functional groups are possible without appreciable loss of activity in most of the aminoglycosides. The 1-amino group of kanamycin A can be acylated (e.g., Amikacin), however, with activity largely retained. Netilmicin (1-N-ethylsisomicin) retains the antibacterial potency of sisomicin and is resistant to several additional bacteria-inactivating enzymes.
**Ring III** functional groups appear to be somewhat less sensitive to structural changes than those of either ring I or ring II.

Although the 2\(^{-}\)-deoxygentamicins are significantly less active than their 2\(^{-}\)-hydroxyl counterparts, the 2\(^{-}\)-amino derivatives (seldomycins) are highly active. The 3\(^{-}\)-amino group of gentamicins may be primary or secondary with high antibacterial potency. Furthermore, the 4\(^{-}\)-hydroxyl group may be axial or equatorial with little change in potency.
Streptomycin Sulfate

Streptomycin Sulfate, Streptomycin acts as a **triacidic base** through the effect of its **two strongly basic guanidino groups** and the more weakly basic methylamino group.

Because streptomycin is not absorbed when given orally or destroyed significantly in the GI tract, at one time it was used **rather widely in the treatment of infections of the intestinal tract**.

For **systemic action, streptomycin usually is given by intramuscular injection**.

Hydroxystreptomycin differs from streptomycin in having a hydroxyl group in place of one of the hydrogen atoms of the streptose methyl group. Mannisidostreptomycin has a mannose residue attached in glycosidic linkage through the hydroxyl group at C-4 of the N-methyl-L-glucosamine moiety.

Acid hydrolysis yields streptidine and streptobiosamine.
Neomycin Sulfate

It is considered one of the most useful antibiotics for the treatment of GI infections. It has broad-spectrum activity against various organisms and shows a low incidence of toxic and hypersensitivity reactions. It is absorbed very slightly from the digestive tract, so its oral use ordinarily does not produce any systemic effect.

Neomycin B differs from neomycin C by the nature of the sugar attached terminally to D-ribose. That sugar, called neosamine B, differs from neosamine C in its stereochemistry.
Chromatography showed that *S. kanamyceticus* elaborates three closely related structures: kanamycins A, B, and C. Commercially available kanamycin is almost pure kanamycin A, the least toxic of the three forms.

The kanamycins do not have the D-ribose molecule that is present in neomycins and paromomycins. Perhaps this structural difference is related to the lower toxicity observed with kanamycins.

Kanamycin A contains 6-amino-6-deoxy-D-glucose
Kanamycin B contains 2,6-diamino-2,6-dideoxy-D-glucose
Kanamycin C contains 2-amino-2-deoxy-D-glucose

The use of kanamycin in the United States usually is restricted to infections of the intestinal tract (e.g., bacillary dysentery) and to systemic infections arising from Gram negative bacilli.
Amikacin

1-N-amino-α-hydroxy butyryl kanamycin A (Amikin), is a semisynthetic aminoglycoside first prepared in Japan.

The synthesis formally involves simple acylation of the 1 amino group of the deoxystreptamine ring of kanamycin A. The remarkable feature of Amikacin is that it resists attack by most bacteria-inactivating enzymes and, therefore, is effective against strains of bacteria that are resistant to other aminoglycosides, including gentamicin and tobramycin.
Gentamicin is composed of a number of related gentamicin components and fractions which have varying degrees of antimicrobial potency. The main components of gentamicin include members of **the gentamicin C complex: gentamicin C1, gentamicin C1a, and gentamicin C2** which compose approximately 80% of gentamicin and have been found to have the highest antibacterial activity. Gentamicin A, B, X, and a few others make up the remaining 20% of gentamicin and have lower antibiotic activity than the gentamicin C complex.
TETRACYCLINE

INTRODUCTION
Most important broad spectrum antibiotics obtained by:
- Fermentation procedures from Streptomyces spp.
- Chemical transformation of natural products
Derivatives of octahydronaphthacene- A hydrocarbon system that comprises four-annulated six-membered rings.

Amphoteric compounds

MECHANISM OF ACTION
• Specific inhibitors of bacterial protein synthesis
Stable chelate complexes are formed by the tetracyclines with many metals, including calcium, magnesium, and iron.

Such chelates are usually very insoluble in water, accounting for the impaired absorption of most (if not all) tetracyclines in the presence of milk; calcium-, magnesium-, and aluminum-containing antacids; and iron salts.

Soluble alkanizers, such as sodium bicarbonate, also decrease the GI absorption of the tetracyclines.

The affinity of tetracyclines for calcium causes them to be incorporated into newly forming bones and teeth as tetracycline–calcium orthophosphate complexes.

The mechanism of staining is tetracycline’s ability to form a complex with calcium ions in a process called chelation.
MECHANISMS OF RESISTANCE
A.) Efflux mediated by trans-membrane spanning
B.) Ribosomal protection
C.) Enzymatic oxidation

GENERAL STRUCTURE

STRUCTURE-ACTIVITY RELATIONSHIP
Positive effects:

- The enolized tricarbonylmethane system at C-1 to C-3 must be intact for good activity.
Aminoalkylation of the amide nitrogen yield derivatives that is more water soluble. (Rolitetracycline)

- Substituents at position 5,5a,6,7,8,9 (hydrophobic “northern and western” faces of the molecule).
- More useful results have been achieved with the introduction of substituents at C-7.
- 6-position: most fruitful site for semisynthetic modification of the tetracyclines.

Negative effects:
- All derivatives containing fewer than four rings are inactive or nearly inactive.
- Replacement of the amide at C-2 with other functions (aldehyde or nitrile) reduces or abolishes activity.
- Monoalkylation of the amide nitrogen reduces activity proportionately to the size of the alkyl group.
- Removal of the 4-dimethylamino group reduces activity.
- Esters of the C-12a hydroxyl group are inactive, with the exception of the formyl ester
Alkylation at C-11a also leads to inactive compounds. Dehydrogenation to form a double bond between C-5a and C-11a markedly decreases activity.

According to source:

- Naturally occurring
  - Tetracycline
  - Chlortetracycline
  - Oxytetracycline
  - Demeclocycline
- Semi-synthetic
  - Meclocycline
  - Methacycline
  - Minocycline
  - Rolitetracycline
According to duration of Action
Short-acting: (half-life is 6-8hrs)

**TETRACYCLINE**

[4-dimethyl amino-1,4,4a,5,5a,6,11,12aoctahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11 dioxo-2-naphthacenecarboxamide]

**Chlortetracycline HCl**
7-chloro-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12aoctahydro3,6,10,12,12a-pentahydroxy-6-
methyl1,11-dioxo-2-naphthacenecarboxamide

**Oxytetracycline HCl**
Chemical analog of chlortetracycline that showed similar antibiotic properties
Long acting: (half-life is 16hrs)
Doxycycline
α-6-deoxy-5-oxytetracycline
Minocycline HCl
7-dimethylamino-6-demethyl-6-deoxytetracycline

CLINICAL USES
Primary Uses:
Treatment for infections caused by:
Mycoplasma pneumoniae
Chlamydiae
Rickettsiae
Vibrios
Spirochetes
Secondary Uses:
Alternative drugs in the treatment of syphilis
Treatment of respiratory infections caused by susceptible organisms
Treatment of leptospirosis
Treatment of acne
Prophylaxis against infection in chronic Bronchitis

Selective Uses:
**Tetracycline**
Treatment of gastrointestinal ulcers caused by Helicobacter pylori

**Doxycycline**
Lyme disease
Prevention of malaria
Treatment of amebiasis
Currently an alternative to macrolides in the initial of community acquired pneumonias

**Minocycline**
Meningococcal carrier state
Demeclocycline
Inhibits the renal actions of antidiuretic hormone (ADH)
Management of patients with ADH-secreting Tumors

TOXICITY
Gastrointestinal disturbances
Bony structures and teeth
Hepatic toxicity
Renal toxicity
Photosensitivity - Especially demeclocycline
Vestibular toxicity - Doxycycline and Minocycline
Chloramphenicol

- Chloramphenicol is an antibiotic useful for the treatment of a number of bacterial infections.
- This includes use as an eye ointment to treat conjunctivitis.
- By mouth or by injection into a vein, it is used to treat meningitis, plague, cholera, and typhoid fever.

History

- Chloramphenicol was first isolated from Streptomyces venezuelae in 1947 and in 1949 a team of scientists at Parke-Davis including Mildred Rebstock published their identification of the chemical structure and their synthesis, making it the first antibiotic to be made instead of extracted from a microorganism.
- In 2007, the accumulation of reports associating aplastic anemia and blood dyscrasia with chloramphenicol eye drops lead to the classification of “probable human carcinogen” according to World Health Organization criteria, based on the known published case reports and the spontaneous reports submitted to the National Registry of Drug-Induced Ocular Side Effects.
Mechanism of Action

- Chloramphenicol is a bacteriostatic by inhibiting protein synthesis.
- It prevents protein chain elongation by inhibiting the peptidyl transferase activity of the bacterial ribosome.
- It specifically binds to A2451 and A2452 residues in the 23s rRNA of the 50s ribosomal subunit, preventing peptide bond formation.
- Chloramphenicol directly interferes with substrate binding in the ribosome, as compared to macrolides, which sterically block the progression of the growing peptide.
Uses

- Chloramphenicol is an antibiotic.
- It's mainly used to treat eye infections (such as conjunctivitis) and sometimes ear infections.
- Chloramphenicol comes as eye drops or eye ointment.
General information

Thiamphenicol is a semisynthetic derivative of chloramphenicol. It differs in that the NO2 group in the para position is replaced by a methylsulfonyl group. The substitution in the para position of the molecule does not influence its effects on either protein or DNA synthesis in any recognizable way. The antibacterial spectrum is almost identical to that of chloramphenicol.

The two drugs are used in similar dosages, although there are large differences in their elimination. Glucuronidation is unimportant for thiamphenicol: over 90% of a therapeutic dose is excreted by the kidneys in unchanged form. The corresponding figure for chloramphenicol is only about 10%. Thus, in contrast to chloramphenicol, the half-life of thiamphenicol is prolonged in patients with reduced renal function in whom accumulation can occur.
• The most important adverse reactions are **an immediate dose-related and reversible disturbance of erythropoiesis and peripheral neuropathy**. In contrast to chloramphenicol, aplastic anemia and **the gray syndrome** do not seem to occur with thiamphenicol. Thiamphenicol is a chloramphenicol analog with a range of activity similar to chloramphenicol, although it is generally 1–2 times less active. It has equal activity against Haemophilus, Bacteroides fragilis and Streptococcus. It differs pharmacokinetically in that it is not eliminated by **hepatic glucuronidation and is excreted unchanged in urine, so elimination is unaffected by liver disease**. Unlike chloramphenicol, thiamphenicol does not cause aplastic anemia in humans.
Florfenicol is a structural analog of thiamphenicol which has greater in vitro activity against pathogenic bacteria than chloramphenicol and thiamphenicol. It is also active against some bacteria that are resistant to chloramphenicol, especially enteric bacteria. Florfenicol is not susceptible to inactivation by chloramphenicol transacetylases; thus some organisms that are resistant to chloramphenicol through this mechanism are susceptible to florfenicol.

In dogs florfenicol is poorly absorbed after SC administration. It has a half-life of less than 5 h. The drug is well absorbed in cats after PO and IM administrations with a similar elimination half-life. It should not be given IV. Florfenicol can cause dose-related bone marrow suppression but has not been reported to cause fatal aplastic anemia in humans.

Florfenicol shows promise as a replacement for other broad-spectrum antibacterials such as sulfonamides and tetracyclines that have been associated with toxicity and residue concerns in food animals. Currently it is approved for use only in cattle, aquaculture and pigs. In cattle it is used to treat infectious conjunctivitis and respiratory disease caused by bacteria like Pasteurella and Haemophilus.
Organic Pharm. Chemistry III

Lecture 8
10\textsuperscript{th} April 2023 (15\textsuperscript{th} April)
11:30 - 2:30

AlNoor University College
Pharmacy Department
2\textsuperscript{nd} Course/ 4\textsuperscript{th} Class
2022/2023
ALLAH MAKES THE IMPOSSIBLE POSSIBLE
INTRODUCTION:

Cancer: group of diseases characterized by uncontrolled growth and spread of abnormal cells that left untreated may lead to death.

Neoplasia: uncontrolled growth of new tissue the product of which is known as tumor & these tumors may be either malignant or benign.

Malignant tumors have the capability of invading surrounding tissues and moving to distant location in the body in process called metastasis that characteristic benign tumors does not posses.

Cancer occurs after normal cells have been transformed into neoplastic cells through alteration of their genetic material and the abnormal expression of certain genes. Neoplastic cells usually exhibit chromosomal abnormalities and the loss of their differentiated properties. These changes lead to uncontrolled cell division and many result in the invasion of previously unaffected organs, a process called metastasis.
Antineoplastic agents, cytotoxics or cytostatics are chemotherapeutic agents used for the treatment of cancer.

The goal of cancer chemotherapy is the selective destruction of malignant tumor cells while sparing normal host cells.

The modern treatment of cancer is being more directed towards combination chemotherapy, in general, after surgery and radiation therapy, which are usually the initial treatments for most solid tumors.

Cancer or tumor is neoplasm (from the Greek, new and formation), which means “a relatively autonomous growth of tissue”.
Cytostatics; Anticancer Agents

Cancer is believed to be a cause of several agents:

- certain chemical compounds,
- radiant energy (including even sun rays), certain viruses,
- pollution agents (water, air and food),
- alimentary deficiency, hereditary factors,
- and cellular mutation of unknown origin.
- Recently, oncogenes are also involved.

According to their localization and shape, malignant tumors receive different names:

- carcinoma (glandular tissue)
- sarcoma (connective tissue)
- Lymphoma (lymphatic ganglia)
- Leukemia (blood cells).
Advances in Cancer Chemotherapy

Treatment options of cancer:

Surgery: before 1955
Radiotherapy: 1955~1965
Chemotherapy: after 1965
Immunotherapy and Gene therapy
The Basic Concept of Cell Generation Cycle

The cycle of cell replication includes:

- M（Mitosis）phase
- G1（Gap1, period before S）phase
- S（DNA synthesis）phase
- G2（Gap2, period after S）phase

Growth Fraction (GF)
Cell cycle Phases
Site of Action of cell-cycle specific Antineoplastics

Cell Cycle Phases

Premitotic synth of structures, mol's

G₂ PHASE

G₂ (Pre-synthesis)

M PHASE

Mitosis (nuclear division)

Cytoplasmic division

M (Mitosis)

INTERPHASE

S PHASE

S (DNA Synthesis)

G₁ PHASE

G₁ (Pre-synthesis)

Synth DNA precursors, proteins, etc.

Non-Cell Cycle Specific --
Alkylation Agents
Antibiotics
Cisplatin
Procarbazine

Antimetabolites --
6-Mercaptopurine
Methotrexate

Epipodophyllotoxins

Bleomycin

G₀ (Resting)
(May not be present)

G₂ (Pre-mitosis)
Anticancer Drugs

Affect cell division
Active on rapidly dividing cells
Most effective during S phase of cell cycle
Many cause DNA damage

Damage DNA $\rightarrow$ initiate apoptosis

Side effects greatest in other rapidly-dividing cells
Bone marrow toxicity
Impaired wound healing
Hair follicle damage
GIT epithelial damage
May themselves be carcinogenic
Classification of Anticancer:

**Cell Cycle Nonspecific Agents (CCNSA)**

Drugs that are active throughout the cell cycle
- Alkylation Agents
- Platinum Compounds
- Antibiotics

**Cell Cycle Specific Agents (CCSA)**

Drugs that act during a specific phase of the cell cycle
- **S Phase Specific Drug:**
  - A. Antimetabolites, Topoisomerase Inhibitors

- **M Phase Specific Drug:**
  - Vinca Alkaloids, Taxanes

- **G2 Phase Specific Drug:**
  - B. bleomycin
Classification of anticancer agents:

- Alkylating agents.
- Antimetabolites.
- Natural products.
- Sex hormones and analogues.
- Miscellaneous cytostatics.
- Radioisotopes.
- Immunosuppressive and immunostimulant drugs.
Site of action
The alkylating agents

The alkylating agents are a class of drugs that are capable of forming covalent bonds with important biomolecules.

There are several potential nucleophilic sites on DNA, which are susceptible to electrophilic attack by an alkylating agent (N-2, N-3, and N-7 of guanine, N-1, N-3, and N-7 of adenine, 0-6 of thymine, N-3 of cytosine).

The most important of these for many alkylating agents is the N-7 position of guanine whose nucleophilicity may be enhanced by adjacent guanine residues. Alkylation converts the base to an effective leaving group so that attack by water leads to depurination and the loss of genetic information if the resulting depurination is not repaired by the cell (Scheme)
Alkylation of 7- Guanine and subsequent depurination of DNA
The general mechanism for alkylation involves nucleophilic attack by —N=, —NH₂, —OH, —O—PO₃H of DNA and RNA, while additional nucleophiles (—SH, COOH, etc.) present on proteins may also react (Scheme).

Anion formation increases the reactivity of the nucleophile compared with the un-ionized form (—O⁻ is more nucleophilic than OH). Reaction with water is also possible, because it represents the nucleophile in greatest abundance in the body and this becomes more likely as the electrophile becomes more reactive. Reaction involves displacement of a leaving group on the electrophile by the nucleophile. The reactivity of the electrophile is dependent in part on the ability of the leaving group to stabilize a negative charge.
The N-7 position of guanine in DNA is strongly nucleophilic. Reaction orders depend on the structure of the alkylating agent. Other base positions of DNA attacked by alkylating agents are

- N-2 & N-3 of guanine
- N-3 & N-1 & N-7 of adenine
- O-6 of thymine and N-3 of cytosine.
- Phosphate Oxygen of DNA is also alkylated to an appreciable extent.

Alkylating agents are also interact with enzymes and other proteins. Alkylating agents could form inter- and intra-strand linkage in DNA.
Nitrogen mustards

The nitrogen mustards are compounds that are chemically similar to sulfur mustard or mustard gas developed and used in World War I. Investigation of sulfur mustard revealed that it possessed antineoplastic properties but because the compound existed as a gas at room temperature. Conversion of the sulfide to a tertiary amine allowed for the formation of salts, which exist as solids at room temperature allowing for easier handling and dosing.

Chlorambucil, melphalan, cyclophosphamide and ifosfamide. The lack of selectivity of mechlorethamine led to attempts to improve on the agent. One rationale was to reduce the reactivity by reducing the nucleophilicity of nitrogen, thereby slowing aziridinium cation formation. This could be accomplished by replacement of the weakly electron-donating methyl group with groups that were electron withdrawing (-I). This is seen in the case of chlorambucil and melphalan by attachment of nitrogen to a phenyl ring (Fig.)
Attachment of more highly electron-withdrawing functionalities was utilized in the case of cyclophosphamide and ifosfamide. In these cases, aziridinium cation formation is not possible until the electron-withdrawing function has been altered.

Chlorambucil is the slowest acting and least toxic of any nitrogen mustard. Used for chronic lymphocytic leukemia. The butonic acid moiety is subjected to β-oxidation to the active phenylacetic acid mustard.

Cyclophosphamide is not active until it is transformed by metabolic process to the active form by hepatic liver Cytochrome P-450 and thus, it could be classified as a bioprecursor prodrug. The metabolic 4-hydroxy derivative is first formed and undergoes the following modifications:
Mechlorethamine is highly reactive, in fact, too reactive and therefore nonselective, making it unsuitable for oral administration and necessitating direct injection into the tumor. In cases of extravasation (drug escapes from the tumor into the underlying tissue), the antidote sodium thiosulfate (Na$_2$S$_2$O$_3$), a strong nucleophile, may be administered.
THIOTEPA

Thiotepa containing the thiophosphoramido functionality was found to be more stable than the oxa-analog (TEPA) but is metabolically converted to TEPA by desulfuration in vivo.

Thiotepa incorporates a less reactive aziridine ring compared with that formed in mechlorethamine. The adjacent thiophosphoryl is electron withdrawing and, therefore, reduces the reactivity of the aziridine ring system.

The conclusion that aziridine is the active alkylating agent once thiotepa has been converted to TEPA is based on the fact that when TEPA is incubated with DNA, no cross links are formed and only mono adducts are generated. The reactivity of aziridine generated by either route may be somewhat enhanced within cancer cells, where the pH is normally reduced 0.2 to 0.4 pH units resulting in an increase in reactivity toward nucleophilic attack.
Acrolein is also formed as a result of this process, which may itself act as an electrophile that has been associated with bladder toxicity. To decrease the incidence of kidney and bladder toxicity, the sulfhydryl (—SH) containing agent mesna may be administered and functions to react with the electrophilic species that may be present in the kidney.
Busulfan utilizes two sulfonate functionalities as leaving groups separated by a four-carbon chain that reacts with DNA to primarily form intrastrand cross-link at 5′-GA-3′ sequences. The sulfonates are also subject to displacement by the sulfhydryl functions found in cysteine and glutathione, and metabolic products are formed as a result of nucleophilic attack by these groups to generate sulfonium species along with methane sulfonic acid.

This is followed by conversion to tetrahydrothiophene, and further oxidation products are subsequently produced to give the sulfoxide and sulfone. The cyclic sulfone known as sulfolane may be further oxidized to give 3-hydroxysulfolane.
Compounds based on platinum that play a central role in many cancer treatment protocols.

The dichloro species is maintained in the blood stream as a result of the relatively high chloride concentration. Movement into the tumor cells is accomplished by passive diffusion or carrier-mediated transport. Once inside the tumor cell, the drug encounters a lower chloride concentration and one chloro group is substituted by a water molecule in a process known as aquation. This serves to “trap” the molecule in the cell as a result of ionization. Reaction with DNA occurs preferentially at the N-7 of guanine of two adjacent guanine residues resulting in primarily (95%) intrastrand cross-links.
Platinum (II) is considered to be a “soft” electrophile and as a result, its complexes are subject to attack by “soft” nucleophiles such as thiol groups found on proteins. This can result in significant protein binding (88%-95%) and inactivation caused by the presence of thiols in albumin, glutathione, and other proteins.
Cisplatin administration is also associated with significant nephrotoxicity and neurotoxicity that is dose limiting. These factors lead to the development of less reactive platinum compounds such as carboplatin and oxaliplatin in which the leaving group was incorporated into a chelate.

**NITROSOUREAS**

General structural requirement
- Urea moiety.
- Nitroso group linked to the urea.
- Electronegative atom with good leaving properties
These compounds are reasonably stable at pH = 4.5 but undergo both acid and base catalyzed decomposition at lower and higher pH, respectively.

Alkylation of DNA involves abstraction of the NH proton, which is relatively acidic (pKa = 8-9), followed by rearrangement to give an isocyanate and a diazohydroxide.

The diazohydroxide, upon protonation followed by loss of water, yields a diazo species that decomposes to a reactive carbocation. The isocyanate functions to carbamylate proteins and RNA, whereas the carbocation is believed to be the agent responsible for DNA alkylation.
• **Procarbazine**

  oxidation of procarbazine does occur in the liver and is mediated by CYP and monoamine oxidase to give azo-procarbazine. This compound may also be generated nonenzymatically in an aerobic environment.

  One such route involves CYP-mediated oxidation of the benzylic methylene carbon with subsequent decomposition to give methyldiazine and the aldehyde. The methyldiazine may then decompose by hemolytic bond cleavage to give methyl and hydrogen radicals along with nitrogen gas or be further oxidized to give the diazo compound, which can decompose to give the methyl carbocation.

  Methylhydrazine covalently bound to the N-7 position of guanine especially on tRNA disrupting its function and preventing protein, RNA, and DNA synthesis.

  There was also a small amount of methylation at the O-6 position of guanine.
Procarbazine $\xrightarrow{\text{CYP or MAO}}$ Azo Procarbazine $\xrightarrow{\text{CYP}}$ Methylidiazene $\xrightarrow{\text{CH}_3\cdot + \text{H}^+ + \text{N}_2}$ DNA alkylation

Diazomethane
Dacarbazine

Activation of the agent occurs through the action of CYP to give the demethylated product monomethyl triazeno imidazole carboxamide (MTIC). Tautomerization allows for decomposition to give the aminocarboxamido-imidazole and diazomethane, which is capable of alkylating DNA. Methylation of DNA occurs at N-7, N-3 and O-6 of guanine among other sites.
Temozolomide

Hydrolysis of temozolomide gives the carboxy-triazene, which spontaneously loses CO$_2$ to give MTIC. Temozolomide may be administered orally.
Organic Pharm. Chemistry III

Lecture 9
11th April 2023 (16th April)
11:30 - 2:30

AlNoor University College
Pharmacy Department
2nd Course/ 4th Class
2022/2023
Lectures titles & Credit hours

AlNoor University College
Pharmacy Department
Department of Pharmaceutical Chemistry
Title of the course: *Organic Pharmaceutical Chemistry III*  Course number:
Level: 4th Class, 2nd Semester
Credit hours/week: Theory 3  Laboratory 1

مدرس المادة : أ.م.د. نهاد عبد الوهاب

**Objectives:** To enable understanding mechanisms of drug action, including antibacterial, antifungal and antiviral agents, at molecular level, and the role of medicinal chemistry in the discovery and development of synthetic therapeutic agents. It also enables students to understand the concept of structure-activity relationship and its application in design and synthesis of new chemotherapeutic agents and hormone derivatives with potential biological activity.

<table>
<thead>
<tr>
<th>Lecture title</th>
<th>hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Lactam antibiotics (Penicillins); β-Lactamase inhibitors; Cephalosporins and Monobactams.</td>
<td>9</td>
</tr>
<tr>
<td>Aminoglycosides and Chloramphenicol; Tetracylines; Macrolides; Lincomycins and Polypeptides; Antiviral agents (properties of viruses, viral classification, products).</td>
<td>9</td>
</tr>
<tr>
<td>Sulfonamides (chemistry, nomenclature, mechanism of action, resistance, toxicity, side effects, metabolism, protein binding, distribution and SAR); products; Sulfones.</td>
<td>4</td>
</tr>
<tr>
<td>Anti-neoplastic agents: Alkylating agents; Antimetabolites; Antibiotics; Plant products; Miscellaneous compounds.</td>
<td>17</td>
</tr>
<tr>
<td>Hormones and related compounds; Future anti-neoplastic agents; Monoclonal antibodies; Gene therapy of cancer.</td>
<td>6</td>
</tr>
</tbody>
</table>
Today’s quote
Cell cycle Phases
Site of Action of cell-cycle specific Antineoplastic drugs

Cell Cycle Phases

- Premitotic synth of structures, mol's
- G2 PHASE
- G1 PHASE
- S PHASE (DNA replication)
- M-phase (Morphological division)
- Interphase

Synth DNA precursors, proteins, etc.

- Site of Action:
  - Cell cycle specific Antineoplastic drugs
  - Non-Cell Cycle Specific Antineoplastic drugs
  - Alkylation Agents
  - Antibiotics
  - Cisplatin
  - Procarbazine
  - Epipodophyllotoxins
  - Antimetabolites
  - 6-Mercaptopurine
  - Methotrexate
  - Bleomycin
  - Hydroxyurea
  - Go (Resting)
  - G1 (Pre-synthesis)
  - G2 (Pre-mitosis)
  - S (DNA Synthesis)

Direction of cycle
Classification of anticancer agents:

- Alkylating agents. (Lec. 1)
- Antimetabolites. (Lec. 2)
- Natural products.
- Sex hormones and analogues.
- Miscellaneous cytostatics.
- Radioisotopes.
- Immunosuppressive and immunostimulant drugs.
Anti Metabolites

- Most antimetabolites are effective cancer chemotherapeutic agents via interaction with the biosynthesis of nucleic acids. Therefore, several of the useful drugs used in antimetabolite therapy are purines, pyrimidines, folates, and related compounds.

- The antimetabolite drugs may exert their effects by several individual mechanisms involving enzyme inhibition at active, allosteric, or related sites. Most of these targeted enzymes and processes are involved in the regulatory steps of cell division and cell/tissue growth.

- Often the administered drug is actually a prodrug form of an antimetabolite and requires activation in vivo to yield the active inhibitor.
The purine and pyrimidine antimetabolites are often compounds incorporated into nucleic acids and the nucleic acid polymers (DNA, RNA, etc.).

The antifolates are compounds designed to interact at cofactor sites for enzymes involved in the biosynthesis of nucleic acid bases. The biosynthesis of these nucleic acid bases depend heavily on the availability of folate cofactors, hence antimetabolites of the folates find utility as antineoplastic agents.
2.A. Pyrimidine Drugs

The anticancer drugs based on pyrimidine structure are shown in Figure

![Anticancer drugs based on pyrimidine and related compounds.](image)
Modification of the pyrimidine ring has also been explored for the
development of potential anticancer drugs based on antimetabolite theory.
5-Fluorouracil is activated by conversion to the corresponding nucleotide
species, 5-fluoro-2-deoxyuridylic acid. The resulting 5-fluoro-2′-
deoxyuridylic acid is a powerful inhibitor of thymidylate synthetase (TS),
the enzyme that converts 2′-deoxyuridylic acid to thymidylic acid. In the
inhibiting reaction, the sulfhydryl group of TS adds via conjugate addition
to the 6-position of the fluorouracil moiety (Scheme 10.19), So the chemical
mechanism of inhibition of TS by 5-fluorouracil is shown in Scheme 10.19
Attempts at chemical modification of 5-FU to protect from catabolic events have produced several prodrug forms, which are converted via in vivo metabolic and/or chemical transformation to the parent drug 5-FU. The carbamate derivative of 5′-deoxy-5-fluorocytidine is known as capecitabine, and it is converted to 5-FU through a series of activation steps. The activation sequence is shown in Scheme 10.21.
The initial step is carbamate hydrolysis(1) followed by deamination(2), then hydrolysis of the sugar moiety(3) to yield 5-FU. **Some of these activation steps take place at a higher rate in tumor tissue leading to selective accumulation in those cells.** The last step in the sequence shown in Scheme 10.21 is catalyzed by phosphorolases, and these enzymes occur in higher levels in colorectal tumors. Despite this complex activation process, **capecitabine** still exhibits some of the significant toxicities of 5-fluorouracil. The tetrahydrofuran derivative **tegafur** is slowly converted to 5-FU but requires quite high doses to reach therapeutic plasma concentrations. Esters of the N-hydroxymethyl derivative of tegafur show greater anticancer activity than tegafur.
Gemcitabine is the result of fluorination of the 2’-position of the sugar moiety. The mechanism of action for gemcitabine includes alteration of the rate of incorporation into DNA as well as the rate of DNA processing and repair.

2.B. Purine Drugs
The anticancer drugs based on purine structure are shown in Figure 10.9.
The design of antimetabolites based on purine structure began with isosteric thiol/sulfhydryl group to replace the 6-hydroxyl group of hypoxanthine and guanine.

6-mercaptopurine (6-MP). This purine requires bioactivation to its ribonucleotide, 6-thioinosinate (6-MPMP), by the enzyme HGPRT. The resulting nucleotide is a potent inhibitor of an early step in basic purine biosynthesis. Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP).
The major antineoplastic action of 6-MP appears to be related to the inhibition of purine biosynthesis.

Thioguanine (6-TG) is the 6-mercapto analog of guanine, analogous to 6-MP. Thioguanine is converted into its ribonucleotide by the same enzyme that acts on 6-mercaptopurine. It is converted further into the diphosphates and triphosphates. These species inhibit most of the same enzymes that are inhibited by 6-mercaptopurine. Thioguanine is also incorporated into RNA, and its 2′-deoxy metabolite is incorporated into DNA. The incorporation into RNA and DNA and the subsequent disruption of these polymers may account for a greater portion of the antineoplastic activity of thioguanine compared with 6-MP.
1. C. Folates
Folic acid and the structures of the major antifolate anticancer drugs are shown in Figure 10.10.
Methotrexate is the classic antimetabolite of folic acid structurally derived by N-methylation of the para-aminobenzoic acid residue (PABA) and replacement of a pteridine hydroxyl by the bioisosteric amino group. The conversion of —OH to —NH2 increases the basicity of N-3 and yields greater enzyme affinity. This drug competitively inhibits the binding of the substrate folic acid to the enzyme DHFR, resulting in reductions in the synthesis of nucleic acid bases, perhaps most importantly, the conversion of uridylate to thymidylate as catalyzed by thymidylate synthetase. In addition, purine synthesis is inhibited because the N-10-formyl tetrahydrofolic acid is a formyl donor involved in purine synthesis.
FLOXURIDINE (FLUORODEOXYURIDINE, FUDR)
The drug is available as a 500-mg vial of lyophilized powder. The drug is used to treat metastatic GI adenocarcinoma. The mechanism of action of this fluoropyrimidine deoxynucleoside analog involves metabolic conversion to 5-fluorouracil (5-FU) metabolites resulting in inhibition of TS thus disrupting DNA synthesis, function, and repair.

GEMCITABINE (DFDC, GEMZAR)
The drug is available as the hydrochloride salt in 200- and 1,000-mg lyophilized single-dose vials for IV use. Gemcitabine is used to treat bladder cancer, breast cancer pancreatic cancer. The mechanism of action of this fluorine-substituted deoxycytidine analog involves inhibition of DNA synthesis and function via DNA chain termination. The triphosphate metabolite is incorporated into DNA inhibiting several DNA polymerases and incorporated into RNA inhibiting proper function of mRNA. Resistance can occur because of decreased expression of the activation enzyme deoxycytidine kinase or decreased drug transport as well as increased expression of catabolic enzymes.
PENTOSTATIN (2’-DEOXYCOFORMYCIN, DCF, NIPENT)
The drug is available in 10-mg vials for IV use. The drug is used to treat leukemias such as hairy cell leukemia, chronic lymphocytic leukemia, and lymphoblastic leukemia. The mechanism of action involves inhibition of the enzyme adenosine deaminase yielding increased cellular levels of deoxyadenosine and deoxyadenosine triphosphate (dATP). The increased levels of dATP are cytotoxic to lymphocytes. Pentostatin is a fermentation product of Streptomyces antibioticus. Resistance appears to involve decreased cellular transport or increased expression of catabolic enzymes. Acid instability prevents oral administration, and the drug is only administered by IV.

PEMETREXED (MTA, ALIMTA)
The drug is available in a 100-mg sterile vial for IV use. The drug appears to be effective against a range of tumors including mesothelioma, NSCLC, colorectal cancer, bladder cancer, and lung cancer. The mechanism of action involves inhibition of TS resulting in inhibition of thymidylate and DNA synthesis. This drug is a pyrrolopyrimidine analog of folate with antifolate activity. Resistance can occur by increased expression of TS, decreased binding affinity for TS, or decreased drug transport into cells.
3. ANTIBIOTICS AND NATURAL PRODUCTS

A variety of the anticancer agents available today are derived from natural sources with several of these being obtained from microbial sources (antibiotics). Many of the antineoplastic antibiotics are produced by the soil fungus Streptomyces. Both the antibiotic and natural product classes have multiple inhibitory effects on cell growth; however, they primarily act to disrupt DNA function and cell division.

There are several mechanisms by which these agents target DNA, including intercalation, alkylation, and strand breakage either directly or as a result of enzyme inhibition. Intercalation is a process by which a planar molecule of the appropriate size inserts itself between adjacent base pairs of DNA and in so doing, it causes a local unwinding that may disrupt the normal template function of DNA. Intercalation requires that the drug induce a cavity between base pairs so that insertion may occur.
There are several natural products that are capable of disrupting the formation and function of the mitotic spindle.

These include the epipodophyllotoxins, the taxanes, and the vinca alkaloids.

The mitotic spindle forms during the M phase of the cell cycle and is responsible for moving the replicated DNA to opposite ends of the cell in preparation for cell division.
1. Epipodophyllotoxins
The epipodophyllotoxins (Fig.) are semisynthetic derivatives of podophyllotoxin, which is isolated from the mayapple (mandrake) root and functions as an inhibitor of microtubule function.
Chemical modification has led to compounds with a different mechanism of action, which involves inhibition of topoisomerase enzymes.
The change in mechanism was associated with removal of the 4′-methyl group of podophyllotoxin. Further alteration in podophyllotoxin involved the addition of the glycosidic portion of the molecules.
Etoposide acts on topoisomerase II stabilizing the cleavable complex leading to single- and double-strand breaks. If enough breaks are initiated, apoptosis is activated.

Etoposide is believed to bind to topoisomerase II in the absence of DNA, because it shows little tendency to interact with DNA alone. The etoposide-topoisomerase II complex then binds DNA, and strand cleavage occurs; however, the ligation step is inhibited. Binding of the drug occurs near the site at which the cleaved phosphodiester bond is held by the enzyme.
Pathway of etoposide-induced DNA cleavage complex formation
Camptothecins
The camptothecins (Fig. 10.16) are inhibitors of topoisomerase I and are used clinically for the treatment of various cancers.

The lead drug for this class of agents was camptothecin, which was isolated from Camptotheca acuminata, an ornamental tree found in China. The mechanism of antitumor action was inhibition of topoisomerase I. Subsequently, the incorporation of side chains containing basic amines led to the more water-soluble derivatives, topotecan and irinotecan (Fig. 10.16).
Irinotecan undergoes hydrolysis of its carbamate moiety by irinotecan-converting enzyme to give SN-38, which is 1,000 times more potent than the parent compound (Scheme 10.29). There is wide interpatient variability in the extent of this transformation, which may explain differential responses to the agent. Further metabolism involves the glucuronidation (isozyme UGT1A1) of the resulting phenolic function of SN-38 to give SN-38G, which is inactive.

An additional metabolite forms as a result of CYP3A4-mediated conversion to [4-N-(5-aminopentanoic acid)-1-piperidino]carbonylcamptothecin (APC), which is 100 times less active than SN-38. There is also the additional complication that the parent and metabolites may exist as the lactones or as the inactive hydroxy acid forms.
1,000 times more potent

Scheme 10.29 • Metabolism of irinotecan.
2. Taxanes

The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as inhibitors of mitosis and which are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers.

Taxanes exert their anticancer effect by inhibiting the mitotic spindle—they bind to the microtubules and prevent their depolymerization, thus inhibiting mitosis and inducing apoptosis in cells undergoing the division process. The drugs are cell-cycle specific in the M-phase.

Briefly, the principal mechanism of Taxol is its ability to stabilize and prevent microtubules depolymerization, leading to cell cycle arrest at the G2/M phase and cell death. However, this effect could be cell lines and dose dependent.
Ovarian cancer, Breast cancer, Non-small cell lung cancer

Paclitaxel

Docetaxel

Semi-synthetic derivatives

Epothilone B

Ixabepilone
The epothilones are macrocyclic lactones that have a mechanism of action similar to that of the taxanes but offer several advantages (Fig. 10.23).

Ixabepilone is the semisynthetic amide analogue of epothilone B that is isolated from the myxobacterium Sorangium cellulosum. The epothilones showed **potent in vitro activity but greatly decreased activity in vivo caused by metabolic instability via hydrolysis of the macrocyclic lactone.** Conversion to the lactam increased stability and maintained in vivo activity. **Ixabepilone has been recently approved for the treatment of metastatic breast cancer that is resistant to the taxanes.** Molecular modeling studies have been utilized to identify a common pharmacophore between the taxanes and epothilones.
Key structural components that assume comparable relative position are indicated in Table 10.2. Like the taxanes, ixabepilone binds to β-tubulin and stabilizes microtubules resulting in cell death. The current indications for the agent are in metastatic breast cancer in combination with capecitabine after the failure of an anthracycline and a taxane and as monotherapy in metastatic breast cancer after failure of an anthracycline, a taxane, and capecitabine.

Major toxicities associated with the use of ixabepilone have included peripheral neuropathy and myelosuppression occurring as neutropenia
3. Vinca alkaloids

The mechanism of action of vinca alkaloids is to **arrest dividing cells in metaphase by binding tubulin and preventing its polymerization into microtubules.**

Vinca alkaloids, including vinblastine, vincristine, vindesine and vinorelbine, are widely used antineoplastic drugs, either as single agents or in combination with other drugs. The mechanism of action of these cell cycle-dependent agents is the inhibition of tubulin polymerisation into microtubules.
3. Vinca alkaloids.
4.PROTEIN KINASE INHIBITORS
Imatinib (Fig. 10.26) was developed to specifically inhibit tyrosine kinase(TK) and does so rather selectively by binding to the ATP-binding pocket and stabilizing an inactive form of the enzyme.
Protein kinases transfer a phosphoryl group from ATP onto target proteins and play a **critical role in signal transduction and other cellular processes**.

Protein kinases are enzymes that phosphorylate (add a phosphate, or PO$_4$, group) to a protein and can modulate its function.

Chemical structures of protein kinase inhibitors. 37: Imatinib (a selective and potent inhibitor of Abl)
38: A potent and selective click-inhibitor of Abl kinase identified from the click-inhibitor library. The Imatinib core structure is highlighted in red. 39 and 40: Click-inhibitors of PfPK7.
Organic Pharm. Chemistry III

Lecture 10 (last)
13th May 2023
11:30-2:30

AlNoor University College
Pharmacy Department
2nd Course/4th Class
2022/2023
Courage doesn’t always roar. Sometimes courage is the quiet voice at the end of the day saying, ‘I will try again tomorrow.’
4.PROTEIN KINASE INHIBITORS
Imatinib (Fig.) was developed to specifically inhibit tyrosine kinase (TK) and does so rather selectively by binding to the ATP-binding pocket and stabilizing an inactive form of the enzyme.
Protein kinases transfer a phosphoryl group from ATP onto target proteins and play a critical role in signal transduction and other cellular processes. Protein kinases are enzymes that phosphorylate (add a phosphate, or PO4, group) to a protein and can modulate its function.

Chemical structures of protein kinase inhibitors. 37: Imatinib (a selective and potent inhibitor of Abl) 38: A potent and selective click-inhibitor of Abl kinase identified from the click-inhibitor library. The Imatinib core structure is highlighted in red. 39 and 40: Click-inhibitors of PfPK7.
Classification of anticancer agents:

- Alkylating agents.
- Antimetabolites.
- Natural products.
- Protein Kinase
- Miscellaneous cytostatics.
- Sex hormones and analogues
- Monoclonal antibody conjugates (Antibody-drug conjugates ADC)
Miscellaneous cytostatics.

1. TEMSIROLIMUS (CCI-779, TORISEL)
2. BORTEZOMIB (VELCADE) :Proteasomes ]
3. Vorinostat
4. ASPARAGINASE (L-ASPARAGINASE, ELSPAR, L-ASNASE, CRISTANASPASE)
5. ESTRAMUSTINE PHOSPHATE SODIUM (EM, EMCYT)
MISCELLANEOUS COMPOUNDS
1. TEMSIROLIMUS (CCI-779, TORISEL)

Temsirolimus is an esterified derivative of rapamycin and in a similar manner binds initially to the protein.
Temsirolimus is a prodrug of rapamycin. It acts to inhibit the mammalian target of rapamycin (mTOR), a serine-threonine kinase that plays a crucial role in cell division. It is somewhat unique in its method of kinase inhibition, because it actually binds to an allosteric modulator of the kinase rather than just binding to the ATP-binding site like most other kinase inhibitors. Binding of temsirolimus inhibits the phosphorylating activity of mTOR.

Binding sites of rapamycin: Green ring (pipecolate region) and purple ring represents binding region to mTOR.
2. BORTEZOMIB (VELCADE)

Proteasomes normally function to degrade proteins that are no longer needed by the cell. Such proteins are normally marked by the addition of ubiquitin, a 76 amino acid protein that is added to the ε-amino group of lysine residues on the target proteins. The marked proteins are then hydrolyzed by the large barrel-shaped proteasomes to give peptides of 7 to 8 residues that may be further hydrolyzed and reutilized by the cell. This process serves to regulate protein levels within the cell, remove defective proteins, and becomes important in maintaining normal signal transduction. Inhibition of the proteasomes results in the build up of ubiquitylated proteins, which disrupts cell-signaling processes and cell growth (Fig.)
3. Vorinostat fits the basic pharmacophore for the HDAC is (Fig.), which consists of a hydrophobic cap region connected to a zinc coordinating functionality by a hydrophobic linker.

hydroxamate histone deacetylase inhibitors (Vorinostat). The structural design consists of a capping group, a carbon linker and a metal binding moiety
Asparaginase is available in 10-mL vials for intramuscular and IV use in the treatment of 
**acute lymphocytic leukemia.** Tumor cells are unable to synthesize asparagine, and 
therefore must utilize what is available in the extracellular environment. 
The agent acts by hydrolyzing extracellular asparaginase to aspartate and ammonia. The 
tumor cells are then **deprived of a necessary nutrient, and protein synthesis is inhibited** 
**leading to cell death.** The agent is specific for the G1 phase of the cell cycle. Resistance 
occurs because of the development of the tumor cells ability to **produce asparagine** 
synthetase that allows them to synthesize the required amino acid.
5. ESTRAMUSTINE PHOSPHATE SODIUM (EM, EMCYT)

Estramustine as the phosphate is available in **140-mg capsules** for the treatment of prostate cancer.

Although originally designed as an alkylating agent, **it has been shown to be devoid of alkylating activity and functions as an inhibitor of microtubule function by binding to microtubule associate proteins (MAPs) and also binds to tubulin at a site that is distinct from that of the vinca alkaloids but thought to partially overlap with that of paclitaxel.**
Classification of anticancer agents:

❖ Alkylating agents.
❖ Antimetabolites.
❖ Natural products.
❖ Protein Kinase
❖ Miscellaneous cytostatics.
1. TEMSIROLIMUS (CCI-779, TORISEL)
2. BORTEZOMIB (VELCADE) :Proteasomes
3. Vorinostat
4. ASPARAGINASE (L-ASPARAGINASE, ELSPAR, L-ASNASE, CRISTANASPASE)
5. ESTRAMUSTINE PHOSPHATE SODIUM (EM, EMCYT)
❖ Sex hormones and analogues
1. Glucocorticoids: Prednisolons and others
2. Estrogens
3. Selective estrogen receptor modulators
4. Selective estrogen receptor down modulators; Fulvestrant
5. Aromatase inhibitors: Aminoglutethamide
6. Antiandrogen: Flutamide, Bicalutamide
7. GnRH analogue: Nafarellin, Leuprorelin, triptorelin
8. Progestins: Medroxyprogesterone acetate, hydroxyprogesterone caproate and megestrol
❖ Monoclonal antibody conjugates (Antibody-drug conjugates ADC)
Sex Hormones and Analogues

1. Glucocorticoids: Prednisolons and others
2. Estrogens
3. Selective estrogen receptor modulators
4. Selective estrogen receptor down modulators; Fulvestrant
5. Aromatase inhibitors: Aminoglutethamide
6. Antiandrogen: Flutamide, Bicalutamide
7. GnRH analogue: Nafarelin, Leuprolelin, triptorelin
8. Progestins: Medroxyprogesterone acetate, hydroxyprogesterone caproate and megestrol

2nd line hormonal therapy for metastatic hormone dependent breast cancer and endometrial cancer.
Hydroxyprogesterone — used in metastatic endometrial Cancer.
A/E: bleeding
9. GnRH antagonists — Cetorelix, Ganirelix, Abarelix
Cetrorelix, ganirelix and abarelix are antagonist of GnRH decrease the release of gonadotropins without causing initial stimulation can be used in prostatic cancer without the risk of flare up reaction.
Sex Hormones and Analogues

It involves the manipulation of the endocrine system through exogenous administration of specific hormones, particularly steroid hormones, or drugs which inhibit the production or activity of such hormones.

Because steroid hormones are powerful drivers of gene expression in certain cancer cells, changing the levels or activity of certain hormones can cause certain cancers to cease growing, or even undergo cell death.

1. Glucocorticoids such as prednisolone and dexamethasone have marked inhibitory effects on lymphocyte proliferation. Used in the treatment of leukaemias and lymphomas.

Their ability to lower raised intracranial pressure, and to mitigate some of the side effects of anticancer drugs, makes them useful as supportive therapy.

Examples

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>dexamethasone</td>
<td>Dexamethasone Intensol</td>
</tr>
<tr>
<td>hydrocortisone</td>
<td>Cortef</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>Medrol</td>
</tr>
<tr>
<td>prednisolone</td>
<td>Orapred, Pediapred, Prelone</td>
</tr>
<tr>
<td>prednisone</td>
<td>Prednisone Intensol</td>
</tr>
</tbody>
</table>
2. Estrogens

Physiological antagonists of androgens.

Thus used to antagonize the effects of androgens in androgen dependent prostatic cancer.

The agonist is occasionally used to treat prostate cancer through suppression of testosterone production.

Diethylstilbestrol and ethinyloestradiol are two oestrogens used clinically in the palliative treatment of androgen-dependent prostatic tumours. The latter compound has fewer side effects. These tumours are also treated with gonadotrophin-releasing hormone analogues.

Oestrogens can be used to recruit resting mammary cancer cells into the proliferating pool of cells, thus facilitating killing by other cytotoxic drugs.

3. Selective estrogen receptor modulators-

Tamoxifen, Toremifene

- Tamoxifen: Non steroidal antiestrogen

Antagonistic: Breast and blood vessels

Agonistic: Uterus, bone, liver, pitutary
4. Selective estrogen receptor down regulators - Fulvestrant

- Pure estrogen antagonist

**Uses:** Metastatic ER+ Breast Cancer in postmenopausal women (*oestrogen receptor* (ER)-positive breast tumours)

**MOA:**
- Inhibits ER dimerization & prevents interaction of ER with DNA
- ER is down regulated resulting in more complete suppression of ER responsive gene function.
5. Aromatase Inhibitors
* Aromatase is the enzyme responsible for conversion of **androstenedione** (androgen precursor) to estrone (estrogenic hormone).
- 1° gen.- Aminoglutethimide
- 2° gen.- Formestane, Fadrozole, Rogletimide
- 3° gen.- Exemestane, Letrozole, Anastrozole

© Aromatase inhibitors (Als) are a class of drugs used in the treatment of breast cancer and ovarian cancer in postmenopausal women.
© As breast and ovarian cancers require estrogen to grow, Aromatase inhibitors are taken to either block the production of estrogen or block the action of estrogen on receptors.

**Aminoglutethimide**

**Mechanism of Action:**
- Inhibitor of adrenal steroid synthesis at the first step, conversion of cholesterol of pregnenolone.
- Inhibits the extra-adrenal synthesis of estrone and estradiol.
- Inhibits the enzyme aromatase that converts androstenedione to estrone.

**ADR:** Dizziness, Lethargy, Visual blurring, Rash
**Therapeutic Uses:** ER- and PR-positive metastatic breast cancer
6. Antiandrogens — Flutamide, Bicalutamide
- Antiandrogens, or androgen antagonists, first discovered in the 1960s, prevent androgens from expressing their biological effects on responsive tissues.
- Antiandrogens alter the androgen pathway by blocking the appropriate receptors, competing for binding sites on the cell's surface, or affecting androgen production.
- Antiandrogens are most frequently used to treat prostate cancer.

7. GnRH analogues — Nafarelin, Leuprolelin, triptorelin
NAFERELIN : nasal spray / SC inj
JFSH & LH release from pituitary- | the release of estrogen & testosterone.
USE : Breast Ca, Prostatic Cancer

8. Progestins: Medroxyprogesterone acetate, hydroxyprogesterone
Caproate and megestrol. 2nd line hormonal therapy for metastatic hormone dependent breast ca and endometrial cancer.
Hydroxyprogesterone — used in metastatic endometrial Cancer.
A/E: bleeding

9. GnRH antagonists — Cetroelix, Ganirelix, Abarelix
Cetroelix, ganirelix and abarelix are antagonist of GnRH decrease the
release of gonadotropins without causing initial stimulation can be used in prostatic ca without the risk of flare up reaction.
Antibody-drug conjugates or ADCs are a new class of drugs designed as a targeted therapy for the treatment of cancer. ADCs are complex molecules composed of an antibody linked, via a stable linker with labile bonds, to a cytotoxic (anticancer) drug.
Structure and mechanism of action of ADCs

Key factors:
- High potency
- High cancer cell specificity
- Low immunogenicity
- Low circulating life
- Low cytotoxicity to off-target cells

Conjugation site: lysine coupling, cysteine alkylation, enzymatic reaction, etc.

Linker: cleavable or non-cleavable

Payload: antimitotic agent

Diagram:
- (1) Binding to cell-surface antigen
- (2) Endocytosis of ADC-antigen complex
- (3) Lysosomal degradation
- (4) Release of active payload
- (5) DNA or microtubule disruption
- (6) Cell death
Antibodies are immunoglobulins made up of:
2 Light Chains (identical) ~25 KDa
2 Heavy Chains (identical) ~50 KDa
From a biology perspective, the design of an effective ADC relies on:

**Target antigen**
- Tumor-specific and homogeneous expression pattern
- High levels of expression
- Rapid internalization
- Minimal ectodomain shedding
- Non-internalizing ADCs challenge internalization as a strict property of target antigens

**Antibody**
- High specificity and affinity for the target antigen
- Favorable PK properties
- Minimal immunogenicity
- Can elicit effector functions
- The majority of ADCs employ human/humanized IgG1 mAbs
- Bispecific antibodies can be used for a more target-specific drug delivery

**Linker**
- Designed to covalently tether the cytotoxic molecule to the antibody scaffold
- Affects several physicochemical parameters ranging from stability in systemic circulation, to solubility and aggregation propensity
- Generally categorized into cleavable and non-cleavable

**Payload**
- The ultimate effector compound
- Super-toxic
- The main categories are: DNA-damaging agents and microtubule-disrupting agents
- Payload classes of FDA-approved ADCs include: Calicheamicins, Auristatins, Maytansinoids, Pyrrolobenzodiazepines and Camptothecin analogues
- Dual-drug ADCs achieve codelivery of warheads with different mechanism of action
Target antigens

A successful ADC should target a well-internalized antigen with low normal tissue expression and high expression on tumors.

Antigen expression on normal tissues can be tolerated if expression on vital organs is minimal or absent.

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Target Antigens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>CD174, GPNMB, CRIPTO &amp; nectin-4 (ASG-22ME)</td>
</tr>
<tr>
<td>Ovarian</td>
<td>MUC16 (CA125), TIM-1 (CDX-014) &amp; mesothelin</td>
</tr>
<tr>
<td>Lung</td>
<td>CD56, CD326, CRIPTO, FAP, mesothelin &amp; GD2</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>CD74, CD227 (MUC-1) &amp; nectin-4 (ASG-22ME)</td>
</tr>
<tr>
<td>Prostate</td>
<td>PSMA, STEAP-1 &amp; TENB2</td>
</tr>
</tbody>
</table>
Schematic diagram of an antibody-drug conjugate (ADC).

Antibody
- High affinity for tumour antigen
- Humanised to decrease immunogenicity
- Long plasma half-life and high molecular weight

Cytotoxic payload
- Highly potent agents—IC_{50} in subnanomolar range
- Microtubule inhibitors: Maytansines, Auristatins
- DNA synthesis inhibitors: Calicheamicin, Doxorubicin, Duocarmycins
- Optimal DAR

Site-specific conjugation
1. Engineered cysteine
2. Enzymatic conjugations
3. Incorporation of UAAs

Non-specific conjugation through lysine or cysteine residues

Noncleavable
- Lysosomal degradation to release drugs

Cleavable
1. Acid sensitive
2. Lysosome protease sensitive
3. Redox sensitive

Linker
- Stable in circulation
- Prevents premature release of payload at non-target tissue
- Efficient release of payload at target site
- Efficient linker technology
- Cleavable versus non-cleavable
- Site of conjugation
- Drug-antibody ratio (DAR) affects drug distribution and pharmacokinetics

Target microtubules
1. Auristatin derivatives
2. Maytansinoids
3. Tubulysins

Target DNA
1. Calicheamicins analogs
2. Duocarmycin analogs
Cytotoxic drugs used in ADC design

The drugs being used to construct ADCs generally fall into two categories:
1) Microtubule inhibitors
2) DNA-damaging agents
ADC advantages over Traditional Chemotherapy:

Traditional Chemotherapy:
- Damages the healthy cells
- Rapid clearance

ADC:
- High binding affinity
- Specificity for tumor cells
- Long half-life
<table>
<thead>
<tr>
<th>Agent</th>
<th>Linker</th>
<th>Warhead</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMMU-110</td>
<td>Hydrazone</td>
<td>Doxorubicin</td>
<td>CD74</td>
</tr>
<tr>
<td>Mylotarg®</td>
<td>Hydrazone</td>
<td>Calicheamicin</td>
<td>CD33</td>
</tr>
<tr>
<td>CMC-544</td>
<td>Hydrazone</td>
<td>Calicheamicin</td>
<td>CD22</td>
</tr>
<tr>
<td>SAR3419</td>
<td>Disulfide</td>
<td>DM4</td>
<td>CD19</td>
</tr>
<tr>
<td>BT-062</td>
<td>Disulfide</td>
<td>DM4</td>
<td>CD138</td>
</tr>
<tr>
<td>BAY-94-9343</td>
<td>Disulfide</td>
<td>DM4</td>
<td>Mesothelin</td>
</tr>
<tr>
<td>SAR-566658</td>
<td>Disulfide</td>
<td>DM4</td>
<td>DS6</td>
</tr>
<tr>
<td>IMGN901</td>
<td>Disulfide</td>
<td>DM1</td>
<td>CD56</td>
</tr>
<tr>
<td>Kadcyla®</td>
<td>Thioether</td>
<td>DM1</td>
<td>HER2</td>
</tr>
<tr>
<td>IMGN529</td>
<td>Thioether</td>
<td>DM1</td>
<td>CD37</td>
</tr>
<tr>
<td>SGN-75</td>
<td>MC</td>
<td>MMAF</td>
<td>CD70</td>
</tr>
<tr>
<td>Adcetris®</td>
<td>Peptide (Val-Cit)</td>
<td>MMAE</td>
<td>CD30</td>
</tr>
<tr>
<td>RG-7596</td>
<td>Peptide (Val-Cit)</td>
<td>MMAE</td>
<td>CD79b</td>
</tr>
<tr>
<td>CDX-011</td>
<td>Peptide (Val-Cit)</td>
<td>MMAE</td>
<td>GPNMB</td>
</tr>
<tr>
<td>PSMA-ADC</td>
<td>Peptide (Val-Cit)</td>
<td>MMAE</td>
<td>PSMA</td>
</tr>
<tr>
<td>ASG-5ME</td>
<td>Peptide (Val-Cit)</td>
<td>MMAE</td>
<td>AGS-5</td>
</tr>
<tr>
<td>IMUU-130</td>
<td>Peptide (Phe-Lys)</td>
<td>SN-38</td>
<td>CEACAM5</td>
</tr>
</tbody>
</table>
Organic Pharm. Chemistry III

Lecture 3
12th March 2023
10:30 - 12:30

AlNoor University College
Pharmacy Department
2nd Course/ 4th Class
2022/2023
However difficult life may seem, there is always something you can do and succeed at.”
- Stephen Hawking. ...

YOU HAVE BEEN MY FRIEND.
THAT IN ITSELF IS A TREMENDOUS THING.

E.B. White

www.RootsOfAction.com
History

The cephalosporins are β-Lactam antibiotics that are closely related both structurally and functionally to the penicillins.

Mechanism of action, mechanism of resistance and some other properties of cephalosporins are identical to penicillins.

Cephalosporins are one of the most widely used antibiotics and are equal in importance to penicillin.
The cephalosporins are isolated from:
- Cephalosprium species
- Prepared semisynthetically.

In 1945

Giuseppe Brotzu`s discovered that cultures of Cephalosporium acremonium inhibited the growth of a wide variety of Gram-positive and Gram-negative bacteria.
Discovered from a fungal colony in Sardinian sewer water (1948)
Cephalosporin C identified in 1961
In 1948 Abraham and his colleagues have been supplied cultures of the fungus and was isolated three principal antibiotic components:

- Cephalosporin P, (a steroid antibiotic that resembles fusidic acid) with minimal antibacterial activity.

- Cephalosporin N, later discovered to be identical with synnematin N (a penicillin derivative now called penicillin N)

- Cephalosporin C.

*Most of the antibiotics introduced since 1965 have been semisynthetic cephalosporins.
Cephalosporin C can be hydrolyzed by acid to 7-aminocephalosporanic acid.

*Compounds containing 7-aminocephalosporanic acid are:
- Relatively stable in dilute acid.
- Highly resistant to penicillinase, regardless of the nature of their side chains and their affinity for the enzyme.
Most cephalosporins are produced semisynthetically by the chemical attachment of side chains to 7-aminocephalosporanic acid.

Cephalosporins

Cephamycin

Cephalosporins (7α-H) and cephamycins (7α-OCH3):

Most natural cephalosporin and cephamycin are not used clinically for side effects, but semi-synthetic products are used.

Objectives of pharmacomodulation:
✓ Broaden the antibacterial spectrum,
✓ Increase resistance to -lactamases,
✓ Improve pharmacokinetics.
Structure of cephalosporins

1. Nomenclature The different families of cephalosporins: according to the substitutions of the cepham.

![Chemical structures of cephalosporins](image)

- **Δ3-cepheine**
- **(6R)-5-thia-1-azabicyclo(4.2.0)oct-2-ene**
- **bicyclo [4.2.0]oct-2-ene**
- **7-αminocephalosporanic acid 7-ACA**
- **(6R,7R)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3-methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene**

Dihydrothiazine ring
B- lactam ring
The different families of cephalosporins: according to the substitutions of cepheme.
Properties of Cephalosporin C

Disadvantages
• Polar due to the side chain - difficult to isolate and purify
• Low potency - limited to the treatment of urinary tract infections where it is concentrated in the urine
• Not absorbed orally

Advantages
• Non toxic
• Lower risk of allergic reactions compared to penicillins
• More stable to acid conditions
• More stable to β-lactamases
• Ratio of activity vs Gram -ve and Gram +ve bacteria is better

Conclusion
• Useful as a lead compound
SAR of Cephalosporins

Similar to penicillins

- The β-lactam ring is crucial to the mechanism
- The carboxylic acid at position 4 is important to binding
- The bicyclic system is important in increasing ring strain
- Stereochemistry is important
- The acetoxy substituent is important to the mechanism

Possible modifications

- 7-Acylamino side chain
- 3-Acetoxy methyl side chain
- Substitution at C-7
Mechanism of Action

The acetoxy group acts as a good leaving group and aids the mechanism
Variation of the 7-Acylamino Side Chain

- Not possible to generate analogues by fermentation
- Not possible to generate analogues by a full synthesis
- Restricted to semi-synthetic procedure

- 7-ACA not available by fermentation
- 7-ACA not available by enzymatic hydrolysis of cephalosporin C
- Generated by a chemical hydrolysis
• Generation of 7-ACA
• Need to hydrolyse a relatively unreactive secondary amide in the presence of a labile β-lactam ring
THE "GENERATIONS" OF CEPHALOSPORINS

First generation cephalosporins
• Spectrum limited to Gram + cocci, mainly Staphylococci and S Streptococci, as well as some enterobacteria.
• Sensitivity to beta-lactamases, poor diffusion in the CSF.

The 3 groups of C1G
1st group: comprising an acetoxyethyl group in 3, hydrolyzed by esterases → low stability.

1st C. semisynthetic Marketed in 1962
2nd group:

- comprising a heterocycle in 3 better stability therefore better pharmacokinetics.
3rd group:

- with a α-amino side chain, contributing to activity by oral route
Useful antibacterial activity of C1G:
• Meti-S staphylococci
• Streptococci (except enterococci)
• Certain Enterobacteriaceae (not producing cephalosporinases):
  Escherichia coli, Klebsiella
• Proteus mirabilis: MS or S

Therapeutic indications of C1G:
• ENT, respiratory, urinary, skin, acute or recurrent infections with sensitive germs
• In IM-IV (1st and 2nd group) / 4 - 8h: dosage = 2 - 12 g / day
• Oral (3rd group): dosage = 2 - 4 g / day
2nd GENERATION CEPHALOSPORINS

✓ Spectrum of activity of C1G but a little more extended for Enterobacteriaceae,
✓ Variable profile depending on the molecule.

STRUCTURES:
✓ a-hydroxylated cephalosporin: cefamandole

![Chemical structure of cefamandole]

✓ Alkoxyiminated cephalosporin: cefuroxime and its esters

![Chemical structure of cefuroxime and its esters]

Alkoxyimine: stabilizes β-lactamases and shifts spectrum to Gram-

R = H cefuroxime (Parenteral sod. Salt) Zinnat®
R= CH(CH3)-O-C(O)-CH3 cefuroxime-axetil (Oral)
✓ Cephamycines:

Useful antibacterial activity of C2G:
- Meti-S staphylococci, streptococci
- Enterobacteriaceae: E. coli, Proteus mirabilis
- H. influenzae: MS or S
- Cefoxitin: anaerobic Gram - bacteria and enterobacteriaceae

Therapeutic indications of C2G:
- Infections caused by germs resistant to C1G and ampicillin, in monotherapy or in combination (aminoglycosides)
- Antibiotic prophylaxis in surgery (CV and orthopedics)
- In IM-IV / 8h: dosage = 2 - 6 g / day
- In Oral route (cefuroxime-axetil): ENT and broncho-pulmonary infections
- dosage = 0.5 - 2 g / day
Organic Pharm. Chemistry III

Lecture 4
12\textsuperscript{th} March 2023
10:30 - 12:30

AlNoor University College
Pharmacy Department
2\textsuperscript{nd} Course/ 4\textsuperscript{th} Class
2022/2023
“Without continual growth and progress, such words as improvement, achievement, and success have no meaning.”

—BENJAMIN FRANKLIN
Third generation cephalosporins

• Considerable increase in activity
• High stability to beta-lactamases: penicillinases, certain cephalosporinases (enterobacteria)
• Dissemination in sites inaccessible to C1G and C2G (meninges)
• Severe hospital infections

Third generation cephalosporins

1. STRUCTURES
• Cephalosporin a-sulfonic: cefsulodine P

H-bond between NH at 7 and the sulfonyl residue: resistance to b-lactamases
- Aminothiazolyl cephalosporin: cefotiam

\[
\text{R} = \text{H} \quad \text{cefotiam,} \\
\text{R} = \text{CH(CH}_{3}\text{)}_{2}-\text{O-CO-O-C}_{6}\text{H}_{11} \\
\text{cefotiam-hexétid} \\
\text{Taketiam}\textsuperscript{®}, \text{Texodil}\textsuperscript{®}
\]

- Aminothiazolyl cephalosporins (oximes)

<table>
<thead>
<tr>
<th>R3</th>
<th>DCI</th>
<th>ND</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>ceftizoxime</td>
<td>Orélox\textsuperscript{®}</td>
</tr>
<tr>
<td>CH\textsubscript{2}-O-CH\textsubscript{3}</td>
<td>cefpodoxime (proxetil)</td>
<td>Claforan\textsuperscript{®}</td>
</tr>
<tr>
<td>CH\textsubscript{2}-O-CO-CH\textsubscript{3}</td>
<td>cefotaxime</td>
<td></td>
</tr>
<tr>
<td>CH\textsubscript{3}-S-</td>
<td>cefmemoxime</td>
<td></td>
</tr>
<tr>
<td>CH\textsubscript{2}-S-</td>
<td>ceftriaxone</td>
<td>Rocéphine\textsuperscript{®}</td>
</tr>
</tbody>
</table>

\[
\text{Cefpodoxime-proxetil} \\
\text{COO-CH(CH}_{3}\text{)}_{2}-\text{O-C(O)-O-CH(CH}_{3}\text{)}_{2}
\]
• Aminothiazolyl-cephalosporins (oximes) continued

Ceftazidime Fortum® Fortumset®
(pentahydrate)
Good activity on Pseudomonas aeruginosa

Cefixime Oroken® (trihydrate)
Vinyl: better stability in an acidic environment, administration by oral route.
.2. Useful antibacterial activity of C3Gs:
- Gram + cocci: staphylococci, penis-S pneumococci
- Gram-cocci: N. gonorrhoeae, meningitidis
- Gram-bacilli: enterobacteria (E. coli, Proteus, Shigella, Salmonella), H. influenzae, P. aeruginosa
- Spirochetes: Borrelia (Lyme disease).

Pharmacokinetic data of C3G:
- Good diffusion (CSF, bile) • t1 / 2 very variable

Therapeutic indications of C3G:
- Severe, localized or generalized infections resistant to other blactams (in particular hospital infections) in monotherapy or in combination
- Antibiotic prophylaxis in surgery
- In IM-IV / 8 - 12 h: dosage = 2 - 6 g / day for oral forms (cefixime and cefpodoxime-proxetil):
OTHER 3rd GENERATION CEPHALOSPORINS
✓ Better stability vis beta-lactamases,
✓ Increased affinity for PLPs,
✓ Good activity on P. aeruginosa,
✓ Better activity on gram-cocci (staphylococci and streptococci).

1. STRUCTURES

.2. Useful antibacterial activity:
• Cocci at Gram + and at Gram –
• Gram bacilli -: enterobacteria

<table>
<thead>
<tr>
<th>Cefepime (2 HCl)</th>
<th>Cefpirome (sulfate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axepim®</td>
<td>Cefrom®</td>
</tr>
</tbody>
</table>
INDICATIONS: Treatment of severe infections, localized or generalized, with bacteria resistant to other β-lactams (in particular hospital infections) as mono therapy or in combination.

Dosage: 2 - 4 g / d

SIDE EFFECTS
They are rather well tolerated.
HEMISYNTHETIC BETA-LACTAMES OF CARBAPENEMS

STRUCTURE-ORIGIN

Isolation of thienamycin: *Streptomyces cattleya*

INTERESTS:

✓ Strong activity on Gram - bacteria;
✓ Bactericidal effect (binding to PLP2; *cysteamine*),
✓ Resistance to β-lactamases in Gram germs -.

*But chemical instability due to the cysteamine residue, hence IMIPENEM*
Protection of the amine in the form of amidine:
✓ Stability,
✓ Better bacteriological activity.

ACCESS ROAD
✓ Fermentation, but total synthesis is preferred,
✓ Passage amine → amidine:

Thienamycin

Imipenem

IMIPENEM

BIOLOGICAL ACTIVITY
Good penetration through the porins of the outer membrane of Gram - germs,
✓ Excellent stability vis-à-vis b-lactamases,
✓ High bactericidal activity
✓ Marked post-antibiotic effect (growth latency after elimination of the antibiotic),
β-lactam Antibiotics

Penicillins
- Penicillin G
- Penicillin V
- Methicillin
- Nafcillin
- Oxacillin
- Cloxacillin
- Dicloxacillin
- Amoxicillin
- Carbenicillin
- Ticarcillin
- Piperacillin
- Mezlocillin
- Cefoxitin
- Azlocillin

Cephalosporins

Carbapenems
- Biapenem
- Ertapenem
- Doripenem
- Imipenem
- Panipenem

Monobactams
- Aztreonam
- Tigemonam
- Carumonam
- Nocardicin A

1st Generation
- Ampicillin
- Cefadroxil
- Cephalexin
- Cephalexin
- Cefadroxil
- Cephalexin
- Cephapirin
- Cephradine

2nd Generation
- Cefazolin
- Cefamandole
- Cefonicid
- Cefmetazole
- Cefotetan
- Cefuroxime

3rd Generation
- Cefaclor
- Cefoperazone
- Ceftizoxime
- Ceftazidime
- Ceftriaxone
- Cefixime
- Moxalactam

4th & 5th Generation
- Cefepime
- Cefozopran
- Cefpirome
- Cefquinome
- Ceftobiprole
- Ceftaroline
- Fosamil
HEMISYNTHESES BETA-LACTAMES Of MONOBACTAMES

MONOBACTAMES
I. ORIGIN
nocardicins (1976);

(2-Oxo-3-aminoazetidin-1-yl) -2-phenylacetic acid

2. CLASSIFICATION - STRUCTURES
• Internal salts: zwitterion

3-Amino-2-oxo azetidine-1-sulfonic acid

Stability b-lactamases, particularly against Gram-, is obtained by substituting the 2-position.

SAR

2-Aminothiazole spectrum → Gram -

Isobutyric chain (ceftazidime) binding on PLP 3 Pseudomonas activity

Sulfonic acid "Activation of the molecule"

Lack of inducing power of β-lactamases
Selective spectrum exclusively on gram bacteria -:
✓ Gram bacilli - : enterobacteria Proteus, Salmonella, Shigella, E.coli, Pseudomonas, Haemophilus;
✓ Gram-cocci: N. gonorrhoeae and meningitidis.

INDICATIONS of AZTREONAM
✓ Severe gram-negative infections (nosocomial infections),
✓ As monotherapy based on the antibiogram data,
✓ **First-line** and in combination (aminoglycoside) in very severe conditions before the antibiogram.
✓ dosage: 3-8 g / d IM or IV (/ 6-8 h).

REATIONS OF AZTREONAM
= well tolerated molecules 7% of prescriptions (in 2% of cases, discontinuation of treatment)
✓ Gastrointestinal effects: diarrhea, nausea and / or vomiting;
✓ Superinfection by gram + germs;
✓ Immuno-allergic reactions (2%)
- low immunogenicity,
- virtual absence of cross reactions with other beta-lactams
HEMISYNTHETIC BETALACTAMES INHIBITORS OF BETALACTAMASES

- SBL (Susceptible Bacteria)
- MBL (Multidrug-Resistant Bacteria)
- Meropenem, a β-lactam antibiotic
- ANT3310, an SBL inhibitor
- ANT2681, an MBL inhibitor

Structures of Avibactam, Clavulanic acid, and Tazobactam are shown.
INTRODUCTION
1.1. Inactivation of beta-lactams
(penicillins, cephalosporins, monobactams)
1.2. Structure of beta-lactamases
✓ Serine enzymes exhibiting a great structural analogy with the PLPs.
✓ Classified according to:
   - Isoelectric pH,
   - Enzymatic constants,
   - The amino acid sequence,
   - Sensitivity or insensitivity to different inhibitors.
1.3. Beta-lactamase biosynthesis
✓ Constitutive (case of Gram - bacteria),
✓ Inducible (induction by methicillin S. aureus betalactamase)
1.4. Biomolecular mechanism of action
Attach Nu of CO of lactame of OH-
Of serine
BETA-LACTAMASES INHIBITORS

- STRATEGIES TO LIMIT THE ACTION OF BETA-LACTAMASES

Design ABTs capable of resisting their action: - penicillins - 2\textsuperscript{nd} and 3\textsuperscript{rd} G cephalosporins.

Decrease their biosynthesis: beta-lactam + chloramphenicol combination

Inhibit them by:
- competitive inhibitors (reversible)
- non-competitive inhibitors = suicide substrates (irreversible)

SAR of \textit{b-lactamase inhibitors}

In chemistry, a nucleofuge (from nucleo- 'atomic nucleus', and fuge 'to run away/escape') is a leaving group which retains the lone pair of electrons from its previous bond with another species.
BETA-LACTAMASES INHIBITORS

3.1. OXAPENAME: clavulanic acid
 Obtained by fermentation of Streptomyces clavuligerus Augmentin ®, Claventin ®

3.1.1. PHYSICO-CHEMICAL CHARACTERS
✓ Potassium clavulanate, very soluble in water,
✓ Identification: IR and NMR
✓ Dosage: HPLC

3.1.2. BIOLOGICAL ACTIVITY
✓ Irreversible inhibitor (= suicide substrate) of beta-lactamases,
✓ Active at low concentration especially on penicillinases,
✓ Weak antibiotic effect by itself.
THERAPEUTIC INTEREST

In combination with penicillin

**Amoxicillin - clavulanic acid Augmentin®**
- Oral absorption of the 2 active ingredient and similar bioavailability.
- Improvement in the performance of amoxicillin against beta-lactamase-producing strains.
- Oral route (1.5 - 2 g) and IV (1 - 12 g).

**Ticarcillin - clavulanic acid Claventin®**
- Improved activity of carboxypenicillin.
- Lack of selection in the hospital environment of bacteria resistant to beta-lactamases.
- Slow IV; dosage: 9 - 18 g.
SULFONYLPENICILLINIC ACIDS

✓ Oxidation derivatives of pename (= sulfone),
✓ Used in the form of sodium salts in combination.

. **Route of access to sulbactam**
Halogenating diazotization - oxidation - hydrogenolysis
Biological activity of sulfonylpenicillins
✓ Irreversible inhibitor of most of the penicillinases produced by Gram + and - bacteria,
✓ Intrinsic antibiotic effect (sulbactam).

Therapeutic benefit of the combination

In association: ampicillin - sulbactam
Unacim® (1 g) (0.5 g)
✓ Poor digestive absorption of sulbactam,
✓ Improvement of the performance of ampicillin, especially against S. aureus,
✓ Oral and slow IV; dosage: 0.75 - 1.5 g / day.

Piperacillin - tazobactam Tazocilline®
✓ Slow IV; dosage = 12 g
USEFUL ANTIBACTERIAL ACTIVITY OF THE ASSOCIATION
✓ Spectrum of associated beta-lactam + irreversible inhibition of betalactamases, produced by germs responsible for severe hospital infections: *Staphylococcus* meti-S, Enterobacteriaceae, anaerobic bacteria including *B. fragilis*

PRECAUTIONS FOR USE
✓ Dividing the doses to avoid high doses of clavulanic acid responsible for diarrhea.
✓ Separate administration of aminosides.
✓ Presence of aspartame (excipient in powders):
✓ **Contraindication**: subjects with phenylketonuria.

CONCLUSIONS
Example of a prodrug: ampicillin + sulbactam (sultamicillin) linked through a methylene bridge.
Lecture 6
26th March 2023
10:30-12:30

AlNoor University College
Pharmacy Department
2nd Course/4th Class
2022/2023
أسأل الله لكم في شهر رمضان.. حسنات تتكاثر وذنوب تتناثر وهموم تتطاير وأن يجعل بسمتكم سعادة وصمتكم عبادة وخاتمتكم شهادة ورزقيكم في زيادة وبكل زخة مطر وبعد من حج واعتمر.. أدعو الله أن يقبل صالح العمل
Macrolides
Introduction

- The macrolides are a class of natural products that consist of a large macrocyclic lactone ring to which one or more deoxy sugars, usually cladinose and desosamine, may be attached.
- The lactone rings are usually 14-, 15-, or 16-membered.
- Macrolides belong to the polyketide class of natural products (Polyketides, a diverse group of heteropolymers with antibiotic and antitumor properties,)

History

- The first macrolide discovered was erythromycin, which was first used in 1952.
- Erythromycin was widely used as a substitute to penicillin in cases where patients were allergic to penicillin or had penicillin-resistant illnesses.
- Later macrolides developed, including azithromycin and clarithromycin, stemmed from chemically modifying erythromycin; these compounds were designed to be more easily absorbed and have fewer side-effects (erythromycin caused gastrointestinal side-effects in a significant proportion of users).
Mechanism of action

- Macrolides are protein synthesis inhibitors.
- The mechanism of action of macrolides is inhibition of bacterial protein biosynthesis, and they are thought to do this by preventing peptidyltransferase from adding the growing peptide attached to tRNA to the next amino acid (similarly to chloramphenicol as well as inhibiting bacterial ribosomal translation. Another potential mechanism is premature dissociation of the peptidyl-tRNA from the ribosome.
- Macrolide antibiotics do so by binding reversibly to the P site on the 50S subunit of the bacterial ribosome.

This action is considered to be bacteriostatic.

- Macrolides are actively concentrated within leukocytes, and thus are transported into the site of infection.
The macrolides are a group of antibiotics produced by various strains of Streptomyces and having a macrolide ring structure linked to one or more sugars. They act by inhibiting protein synthesis, specifically by blocking the 50S ribosomal subunit. They are broad spectrum antibiotics.

- Azithromycin,
- Clarithromycin,
- Examples: Erythromycin, Roxithromycin etc.
Objectives:
1. Understand the chemistry of drug with respect to their biological activity.
2. Know the Importance of SAR of Drugs
3. Know the metabolism, Adverse Effect and therapeutic value of drugs.
4. Understand the importance of Drug design.

Learning Outcomes:
1. Students will Learn about the structures and Medicinal uses of Drugs.
2. Students will learn about relation of structure with its activity.
3. Students will Learn about the designing of drugs.
SOURCE:

These Are Produced By Streptomyces species.

CHEMISTRY:
- A macrocyclic lactone, usually having 12 to 17 atoms.
- A ketone group.
- One or two amino-sugars linked to the nucleus.
- A neutral sugar linked either to amino sugar or to lactone ring.
- The presence of the dimethylamino moiety on the sugar residue, which explains the basicity of these compounds and consequently formation salts.
SAR

- As macrolide are unstable in acidic pH, a no. of strategies have been utilized to improve the acidic stability of erythromycin.
- The addition of hydroxylamine to the ketone to form oxime e.g. roxithromycin
- Alteration of c-6hydroxyl group: nucleophilic functionality which initiates erythromycin degradation.
- The azalides (azithromycin) are semi-synthetic 15-membered congeners in which a nitrogen atom has been introduced to expand a 14-membered precursor-leads to an extended spectrum of action.
Physical & Chemical properties

- Water insoluble molecules.
- Occurs as crystalline powders.
- Stable in aqueous solutions at or below room temperature.
- Unstable in acidic conditions and forms internal cyclic ketal
Mechanism of action

- Macrolide is protein biosynthesis inhibitors

Macrolide bind to 50S ribosomal subunit

Inhibit polypeptide chain elongation & protein synthesis inhibition

Result in inhibition of growth & multiplication
Inhibition of Protein Synthesis by Antibiotics

Growing peptide

Chloramphenicol binds to 50S r-RNA and inhibits formation of peptide bond

Erythromycin binds to 50S r-RNA and prevents movement along m-RNA

Streptomycin changes shape of 30S r-RNA and causes m-RNA to be read incorrectly

Tetracycline interferes with the t-RNA anticodon reading of m-RNA codon

C. Ophardt, c. 2003
Study of Structure-Activity Relationships

Functional elements of Erythromycin essential for the induction of antibacterial activity

Erythromycin inactivation and pharmacomodulation sites
Weak point of Erythromycin A

- It is the ketone function in position C9, hydroxyl groups in C6 and C12 and hydrogen in position C8 in its beta conformation. These entities are responsible for the acetalization reaction which leads to the hemiketal and spiroketal derivatives responsible for the digestive intolerance of Erythromycin A.

- Another weak point of Erythromycin A is the presence of L-cladinose in position 3. Indeed, in gastric acid medium, the hydrolysis of the latter occurs to form an inactive 3-hydroxy erythromycin A derivative; which would inevitably favour the appearance of drug-resistant germs.
Pharmacochemical Evolution of Erythromycin A to Neomacrolides
Pharmacochemical Evolution of Erythromycin A to Neomacrolides

In order to obtain more effective hemisynthesis derivatives or neomacrolides of Erythromycin A, various chemical variations were made at its pharmacomodulable sites. These include chemical variations at the sites carried by carbons C3, C6, C8, C9, C11 and C12.

These different pharmacomodulations have led to neomacrolides having higher pharmacokinetic performance, better digestive tolerance and/or a broader antibacterial spectrum compared to Erythromycin A.

The neomacrolides are classified according to the size of the 14- or 15-membered rings macrocycle. Thus the 14-membered ring derivatives are composed of Clarithromycin, Roxithromycin, Erythromycylamine, Dirithromycin and Flurithromycin.

Only one 15-membered neomacrolide is currently used in therapy, it is Azithromycin. The different pharmacomodulations undertaken around the chemical structure of Erythromycin A can be summarized in

- one esterification and salification,
- chemical modulation of the C6 hydroxyl function,
- halogenation of C8 and
- chemical modulation of the ketone function in C9.
I. Esterification and Salification of Erythromycin A

In order to **mask the bitter taste** of Erythromycin A, the hydroxyl in position C2’ of D-desosamine (Figure) has been **esterified**. The Erythromycin esters obtained have **shown better stability in an acid medium**, but still require repeated administration. Indeed, pharmacokinetic evaluations of **Erythromycin stearate and Erythromycin ethyl succinate** administered orally have shown that their absorption is **influenced by meals**. In addition, stearate, ethyl succinate, estolate, propionate and acistrate of Erythromycin A have enabled preparing **intramuscular injectable forms**.
In order to obtain formulations for intravenous use, various salts of Erythromycin A have been prepared. The salification concerned the dimethylamine group at C3’ of D-desosamine. The salts for therapeutic use obtained were in particular salts of glucoheptonate. A stoichiometric mixture of Erythromycin base with one of these salts is able to obtain an intravenous formulation. However, these salts have the drawback of having inconsistent pharmacokinetics and of causing venous irritations like the phlebitis.
II. Chemicals Modulations at C6 and C8: Clarithromycin and Flurithromycin

The hydroxyl at C6 involved in gastric acid medium in the hemiacetalization reaction with the ketone function at C9, was blocked by O-methylation thus leading to **O6-methyl erythromycin A** or **Clarithromycin** (Figure). This new molecule has shown an activity greater than or equal to that of Erythromycin A against respiratory pathogens with an increased antibacterial activity against Haemophilus influenzae, due to its active metabolite 14-hydroxyclarithromycin which acts in synergy with the parent molecule. In addition, Clarithromycin is more stable in an acid environment and therefore has fewer gastrointestinal side effects.

However, the presence of hydroxyl at position C12 and the ketone function at position C9 lead to a degradation of Clarithromycin in an acid medium, to pseudo-Clarithromycin which is inactive.
Chemicals Modulations at C6 and C8: Clarithromycin and Flurithromycin (cont.)

The hydrogen at β at the C8 position involved in the degradation of Erythromycin A in gastric acid medium has been replaced by a halogen atom, in this case fluorine. This fluorine atom minimizes the metabolism of the molecule. This strategy made it possible to obtain Flurithromycin.

Flurithromycin has the advantage of being more stable in an acid environment. Indeed, the dehydration in C8 of Erythromycin A in anhydrohemiketal is prevented by the addition of the fluorine atom. Thus, the enolization of the ketone in C9 is annihilated. This improved stability is characterized by a prolonged half-life time at the origin of its once-daily administration.

Flurithromycin exhibited two to four times the antibacterial activity of Erythromycin A due to its inhibitory effects on the formation of the bacterial ribosome 30S subunit.
Chemical Modulation of the Ketone Function in C9

In order to prevent the formation of the inactive 6,9-hemiketal, and therefore to compensate for the degradation in gastric acid medium of Erythromycin A, its ketone function at C9 has previously been transformed into an N-9-oxime derivative. The latter, serving as a synthesis intermediary, subsequently underwent several chemical variations. This chemical variation at C9 ketone has led to the development of **Roxithromycin, Clarithromycin, Erythromycylamine, Dirithromycin** and **Azithromycin**.
The first was an O-alkylation reaction of the hydroxyl of the oxime function, thus leading to the production of ether oximes including **Roxithromycin, the first hemisynthetic macrolide**. Roxithromycin has better stability in an acid environment and good digestive absorption, hence an increase in its bioavailability by oral route ranging from **72% to 85%**. In addition, Roxithromycin has a weaker binding to cytochrome P450 associated with an exaltation of the elimination half-life time of the order of 12 hours, resulting in **twice-daily administration**. On the other hand, its spectrum of antibacterial activity remains **equivalent to that of Erythromycin A**.
The second reaction undertaken on the N-9-oxime derivative of Erythromycin A was its reduction to an amine function. This modulation made it possible to obtain Erythromycylamine, which is very active on bacterial germs. Unfortunately, this N-9-amine from Erythromycin A has the major drawback of being poorly absorbed orally due to the presence of the protonable amine function, which is therefore difficult to cross the digestive membranes.
To improve membrane crossings, Erythromycylamine underwent heterocyclization through its amine functions at C9, hydroxyl at C11 and under the action of an acetaldehyde. Such heterocyclization led to the formation of a bicycle of Erythromycin A or 1,3-oxazinane of Erythromycin A also called Dirithromycin.

Dirithromycin is actually a prodrug, because in an acidic environment, it rapidly transforms into Erythromycylamine. It appears to have a good tissue concentration after oral administration, a low potential for interaction with cytochrome P450 a large volume of distribution (11 - 100 L/kg) and a half-life of high elimination (20 - 50 hours), resulting in once-daily administrations. However, the antibacterial activity spectrum of Dirithromycin in vitro is similar to that of Erythromycin A with low oral bioavailability (10%)
The latest reaction to the N-9-oxime derivative of Erythromycin A was that of the Beckmann rearrangement. It led to the enlargement of the lactonic macrocycle from 14-membered ring to a new macrocycle with 15-membered ring following the introduction of a nitrogen atom which undergoes methylation in the end. These are the **Azalides, the leader of which is Azithromycin.** In the end, Azithromycin or 9-deoxo-9a-aza-9a-methyl-homoerythromycin A has become one of the most effective antibiotics in the world and currently contributes, due to its exceptional therapeutic properties, to the improvement of quality of life globally.
Antibacterial Targets:

Cell Wall Synthesis Inhibition
- β-lactams
- Glycopeptides
- Daptomycin
- Tunicamycin
- Bacitracin

Protein Synthesis Inhibition
- Aminoglycosides
- Tetracyclines
- Macrolides
- Oxazolidinones
- Streptogramins
- Lincosamides

Metabolism Inhibition
- Sulfamethoxazole
- Trimethoprim
- Quinolones
- Novobiocin

DNA Synthesis Inhibition
- Rifampin

RNA Synthesis Inhibition
Bacterial DNA Synthesis: Gyrase and Topo IV: Quinolone Inhibitors

**Cooperative Binding Model:**
- drug binds to cleaved single-stranded DNA and thereby traps the enzyme
- four quinolone molecules bind cooperatively to DNA via H-bonds to DNA bases
- quinolones stack onto each other to form pairs
- quinolones aggregate via substituents at 1 and 8 position

**Mg2+ Bridge Model:**
- drug binds to DNA phosphates via chelation of Mg2+
- quinolone ring stacks onto DNA bases
- quinolone binding induces a conformational change in the gyrase-DNA complex
- cleavage of DNA is not necessary for drug binding

[Diagram of quinolone structure with labels for stacking and hydrogen bonding]
Synthetic compounds discovered 1962 as a by-product of an antimalarial program.

- Not used as antibiotics until discovery of improved 6-fluoroquinolones in 1980s (norfloxacin).
- Orally bioavailable; excellent distribution; active against G+/-
- Resistance development can be rapid by target modification (mutation in the quinolone resistance determining region QRDR of gyrase/topo IV) and by active efflux.

R; -COOH, -COOR'; Coumarin, penems, carbapenems or monobactam etc.
R₁; halo atom, halo substituted aromatic ring, hetero atom, (substituted) C₁-6 alkyl, (Substituted) C₃-6 cycloalkyl, (Substituted) aryl etc.
R₂; H, -SCH₃, C₁-6 alkylthio, or R₂ & R₁ may join to form a ring.
Bacterial DNA Synthesis: Gyrase and Topo IV: Quinolone Inhibitors

1) **First generation**: nalidixic acid, oxolinic acid, pipedonic acid, **flumequine**, ...

2) **Second generation (most potent against Pseudomonas)**: norfloxacin, ciprofloxacin, enoxacin, fleroxacin, **ofloxacin**, levofloxacin, lomefloxacin, ...

3) **Third generation (more potent against Pneumococcus and anaerobes)**: sparfloxacin, tosufloxacin, gatifloxacin, pazufloxacin, grepafloxacin, ...

4) **Fourth generation (most potent against Pneumococcus and anaerobes)**: trovafloxacin, clinafloxacin, sitafloxacin, moxifloxacin, **gemifloxacin**
Phototoxicity of fluoroquinolones with halogen substituents at 8-position

<table>
<thead>
<tr>
<th>Drug</th>
<th>X8</th>
<th>R1</th>
<th>R5</th>
<th>R7</th>
<th>Phototoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gatifloxacin</td>
<td>COCH₃</td>
<td></td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td></td>
<td>O-CH₃CH₃</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>CH</td>
<td></td>
<td>H</td>
<td>H</td>
<td>+</td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>CH</td>
<td>C₂H₅</td>
<td>H</td>
<td>H</td>
<td>+</td>
</tr>
<tr>
<td>Enoxacin</td>
<td>N</td>
<td>C₂H₅</td>
<td>H</td>
<td>H</td>
<td>++</td>
</tr>
<tr>
<td>Fleroxacin</td>
<td>CF</td>
<td>CH₂CH₂F</td>
<td>H</td>
<td>H</td>
<td>++</td>
</tr>
<tr>
<td>Lomefloxacin</td>
<td>CF</td>
<td>C₂H₅</td>
<td>H</td>
<td>H</td>
<td>+++</td>
</tr>
<tr>
<td>Sparfloxacin</td>
<td>CF</td>
<td></td>
<td>NH₂</td>
<td>H</td>
<td>+++</td>
</tr>
</tbody>
</table>

Phototoxic potential was assessed by the results of the thickness and histopathological findings of the auricle at 96h post-dose. The auricular thickness of lomefloxacin and sparfloxacin was estimated at 48h post-dose because the auricles showed focal loss and could not be measured after this timepoint. (-) none, (+) mild, (++) moderate, (+++) severe.
Phototoxicity of fluoroquinolones with halogen substituents at 8-position
- Sparfloxacin (Zagam, Mylan/Aventis); approved 1996; withdrawn 1998 due to phototoxicity
- Clinafloxacin (Warner Lambert/Pfizer); stopped clinical development due to phototoxicity

• Animal studies show joint & cartilage damage in weight-bearing joints of young animals (dogs; effect animal- & dose-dependent)
- All fluoroquinolones have shown this toxicity
- Mechanism unclear
- Fluoroquinolones not approved for use in children (except in CF)
- Compassionate use cases suggest that this toxicity is very rare in children

ABT-492 (WQ-3034)

• QT interval prolongation (hERG) observed with some fluoroquinolones
- Grepafloxacin (Raxar, Glaxo); approved 1997; voluntarily withdrawn 1999
RNA SYNTHESIS INHIBITION: Rifamycins

Cell Wall Synthesis Inhibition
- β-lactams
- Glycopeptides
- Daptomycin
- Tunicamycin
- Bacitracin

Protein Synthesis Inhibition
- Aminoglycosides
- Tetracyclines
- Macrolides
- Oxazolidinones
- Streptogramins
- Lincosamides

Metabolism Inhibition
- Sulfamethoxazole
- Trimethoprim

DNA Synthesis Inhibition
- Quinolones
- Novobiocin

RNA Synthesis Inhibition
- Rifampin
Rifampin

- **Ansamycin class antibiotic**
- semisynthetic rifamycin derivative
- isolated 1957 from *Nocardia Mediterranei*
- inhibits selectively bacterial RNA polymerase by binding to the β-subunit, >12Å away from the active site
- binding site is highly conserved among bacteria but not in eukaryotic RNAPs
- blocks the exit path of elongating RNA when transcript is 2-3 nucleotides in length
- **bacteriostatic**
- active against G+/-, however MICs for G- are higher because of reduced outer membrane penetration
- primarily used against Mycobacteria (tuberculosis, leprosy) and Meningococci
- resistance develops easily by RNAP mutations that reduce target affinity
- often used in combination with other bactericidal antibiotics
The Organic Chemistry of Drug Design and Drug Action

BY:
Dr. Nohad A AlOmar (B.Pharm/MSc & PhD in Medicinal Chemistry)
Organic Pharm. Chemistry III

Lecture 1
20th February (5th March)
10:30 - 12:30

AlNoor University College
Pharmacy Department
2nd Course/ 4th Class
2022/2023
Today’s Inspiring Quote

To find optimism, look for the good things in life.

-Catherine Pulsifer
AlNoor University College
Pharmacy Department
Department of Pharmaceutical Chemistry
Title of the course: *Organic Pharmaceutical Chemistry III*  Course number:
Level: 4\(^{th}\) Class, 2\(^{nd}\) Semester
Credit hours/week: **Theory 3**  **Laboratory 1**

مدرس المادة :-- أ.م.د.نهاد عبد الوهاب

**Objectives:** To enable understanding mechanisms of drug action, including antibacterial, antifungal and antiviral agents, at molecular level, and the role of medicinal chemistry in the discovery and development of synthetic therapeutic agents. It also enables students to understand the concept of structure-activity relationship and its application in design and synthesis of new chemotherapeutic agents and hormone derivatives with potential biological activity.

<table>
<thead>
<tr>
<th>Lecture title</th>
<th>hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Lactam antibiotics (Penicillins); β-Lactamase inhibitors; Cephalosporins and Monobactams.</td>
<td>9</td>
</tr>
<tr>
<td>Aminoglycosides and Chloramphenicol; Tetracylines; Macrolides; Lincomycins and Polypeptides; Antiviral agents (properties of viruses, viral classification, products).</td>
<td>9</td>
</tr>
<tr>
<td>Sulfonamides (chemistry, nomenclature, mechanism of action, resistance, toxicity, side effects, metabolism, protein binding, distribution and SAR); products; Sulfones.</td>
<td>4</td>
</tr>
<tr>
<td>Anti-neoplastic agents: Alkylating agents; Antimetabolites; Antibiotics; Plant products; Miscellaneous compounds.</td>
<td>17</td>
</tr>
<tr>
<td>Hormones and related compounds; Future anti-neoplastic agents; Monoclonal antibodies; Gene therapy of cancer.</td>
<td>6</td>
</tr>
</tbody>
</table>
PENICILLINS

Lec. 1
20/02/2023
• Antibacterial agents which inhibit bacterial cell wall synthesis
• **Discovered by Fleming from a fungal colony (1928)**
• Shown to be non toxic and antibacterial
• Isolated and purified by Florey and Chain (1938)
• First successful clinical trial (1941)
• Produced by large scale fermentation (1944)
• Structure established by X-ray crystallography (1945)
• 1945: Nobel Prize A. Fleming / H. Florey; E. B. Chain
• 1947: Nobel Prize in Chemistry Robert Robinson performs the first synthesis of penicillin.
• Full synthesis developed by Sheehan (1957)
• Isolation of 6-APA by Beechams (1958-60)
  - development of semi-synthetic penicillins
• Discovery of clavulanic acid and β-lactamase inhibitors
Side chain varies depending on carboxylic acid present in fermentation medium

- Benzyl penicillin (Pen G): $\text{CH}_2\text{CO}_2\text{H}$, present in corn steep liquor
- Phenoxymethyl penicillin (Pen V): $\text{OCH}_2\text{CO}_2\text{H}$, (first orally active penicillin)
Shape of Penicillin G

Folded ‘envelope’ shape
Biosynthesis of Penicillins

(a) 
(b) 

CYS

VAL

H₃C

CO₂H

NH₂

CH₃

CO₂H
Properties of Penicillin G

- Active vs. Gram +ve bacilli and some Gram -ve cocci
- Non toxic
- Limited range of activity
- Not orally active - must be injected
- Sensitive to β-lactamases
  - (enzymes which hydrolyse the β-lactam ring)
- Some patients are allergic
- Inactive vs. Staphylococci

Drug Development

Aims
- To increase chemical stability for oral administration
- To increase resistance to β-lactamases
- To increase the range of activity
Conclusions

• Amide and carboxylic acid are involved in binding
• Carboxylic acid binds as the carboxylate ion
• Mechanism of action involves the β-lactam ring
• Activity related to β-lactam ring strain (subject to stability factors)
• Bicyclic system increases β-lactam ring strain
• Not much variation in structure is possible
• Variations are limited to the side chain (R)
Penicillins inhibit a bacterial enzyme called the transpeptidase enzyme which is involved in the synthesis of the bacterial cell wall.

- The β-lactam ring is involved in the mechanism of inhibition.
- Penicillin becomes covalently linked to the enzyme’s active site leading to irreversible inhibition.

Covalent bond formed to transpeptidase enzyme
Irreversible inhibition
Mechanism of action - bacterial cell wall synthesis

Bond formation inhibited by penicillin
Mechanism of action - bacterial cell wall synthesis

D-Alanine TRANSPEPTIDASE PENICILLIN

SUGAR BACKBONE


D-Alanine

TRANSEPTIDASE

PENICILLIN

Cross linking
Penicillin inhibits final cross linking stage of cell wall synthesis. It reacts with the transpeptidase enzyme to form an irreversible covalent bond. Inhibition of transpeptidase leads to a weakened cell wall. Cells swell due to water entering the cell, then burst (lysis). Penicillin possibly acts as an analogue of the L-Ala-g-D-Glu portion of the pentapeptide chain. However, the carboxylate group that is essential to penicillin activity is not present in this portion.

https://www.google.com/search?q=why+penicillin+inhibit+transpeptidase+enzyme&rlz=1C1GCEA_enIQ982IQ982&ssrs=AJQqlzVi_UnmRLEmolMWzOfZXb0Vfhdg:1677689572191&source=lnms&tbs=vid:sa=X&ved=2ahUKEwiznfnXm9a9AhU_R_EDHxMxA18Q_AUoAXoECAEQCg&biw=1292&bih=735&dpr=0.8#fpstate=ive&vld=cid:640ee296,vid:a81nHSqQuvI
**Mechanism of action - bacterial cell wall synthesis**

**Alternative theory** - Pencillin mimics D-Ala-D-Ala.

**Normal Mechanism**
**Mechanism of action - bacterial cell wall synthesis**

**Alternative theory** - Pencillin mimics D-Ala-D-Ala.

**Mechanism inhibited by penicillin**

[Diagram showing the mechanism of action with labeled molecules and blocked parts.]
Mechanism of action - bacterial cell wall synthesis

Penicillin can be seen to mimic acyl-D-Ala-D-Ala

But 6-methylpenicillin is inactive despite being a closer analogue
Mechanism of action - bacterial cell wall synthesis

Penicillin may act as an ‘umbrella’ inhibitor
Gram +ve and Gram -ve Cell Walls

- Penicillins have to cross the bacterial cell wall in order to reach their target enzyme.
- Cell walls are porous and are not a barrier.
- The cell walls of Gram +ve bacteria are thicker than Gram -ve cell walls, but the former are more susceptible to penicillins.
Gram +ve and Gram -ve Cell Walls

Gram +ve bacteria

- Thick cell wall
- No outer membrane
- More susceptible to penicillins
Gram +ve and Gram -ve Cell Walls

Gram -ve bacteria

- Thin cell wall
- Hydrophobic outer membrane
- More resistant to penicillins
Mechanisms of action

Bacteriostatic action

b-lactams are reversible transpeptidase inhibitors (PLP) which bind pentaGly to the tetrapeptide.

The PLP substrate is therefore the D-Ala-D-Ala residue of the precursor

Bactericidal action

Other mechanisms of action

The b-lactams induce the release of inhibition of various autolytic systems, in particular murein hydrolase which splits the bond between N-acetylmuramic acid and alanine → disorganization of the peptidoglycan → lethal effect → Bactericidal action
Resistance to Penicillins

Factors
• Gram -ve bacteria have a lipopolysaccharide outer membrane preventing access to the cell wall
• Penicillins can only cross via porins in the outer membrane
• Porins allow small hydrophilic molecules such as zwitterions to cross

• High levels of transpeptidase enzyme may be present
• The transpeptidase enzyme may have a low affinity for penicillins (e.g. PBP 2a for S. aureus)

• Presence of b-lactamases
• Concentration of b-lactamases in periplasmic space

• Mutations
• Transfer of b-lactamases between strains
• Efflux mechanisms pumping penicillin out of periplasmic space
Penicillin Analogues - Preparation

1) By fermentation
   • Vary the carboxylic acid in the fermentation medium
   • Limited to unbranched acids at the α-position i.e. RCH₂CO₂H
   • Tedious and slow

2) By total synthesis
   • Only 1% overall yield
   • Impractical

3) By semi-synthetic procedures
   • Use a naturally occurring structure as the starting material for analogue synthesis
Penicillin Analogues - Preparation

Fermentation →

Penicillin acylase or chemical hydrolysis

6-APA

Semi-synthetic penicillins
Penicillin Analogues - Preparation

Problem - How does one hydrolyse the side chain by chemical means in presence of a labile β-lactam ring?

Answer - Activate the side chain first to make it more reactive

Note - Reaction with PCl₅ requires the involvement of a lone pair of electrons from nitrogen. Not possible for the β-lactam nitrogen.
Problems with Penicillin G

• It is sensitive to stomach acids

• It is sensitive to β-lactamases - enzymes which hydrolyse the β-lactam ring

• It has a limited range of activity
Problem 1 - Acid Sensitivity

Reasons for sensitivity

1) Ring strain

Acid or enzyme

Relieves ring strain
Problem 1 - Sensitivity

Reasons for sensitivity

2) Reactive β-lactam carbonyl group
Does not behave like a tertiary amide

Tertiary amide

β-Lactam

• Interaction of nitrogen’s lone pair with the carbonyl group is not possible
• Results in a reactive carbonyl group
Problem 1 - Sensitivity

Reasons for sensitivity

Acyl side chain

Neighboring group participation in the hydrolysis mechanism

Further reactions
Problem 1 - Sensitivity

Conclusions

• The β-lactam ring is essential for activity and must be retained
• Cannot tackle factors 1 and 2
• Can only tackle factor 3

Strategy

Vary the acyl side group (R) to make it electron-withdrawing to decrease the nucleophilicity of the carbonyl oxygen

Decreases nucleophilicity
Problem 1 - Sensitivity

Examples

Penicillin V
(orally active)

- Better acid stability and orally active
- But sensitive to b-lactamases
- Slightly less active than penicillin G
- Allergy problems with some patients

Very successful semi-synthetic penicillins
e.g. ampicillin, oxacillin
Problem 2 - Sensitivity to β-Lactamases

β-Lactamases

- Enzymes that inactivate penicillins by opening β-lactam rings
- Allow bacteria to be resistant to penicillin
- Transferable between bacterial strains (i.e. bacteria can acquire resistance)
- Important with respect to *Staphylococcus aureus* infections in hospitals
- 80% *Staph.* infections in hospitals were resistant to penicillin and other antibacterial agents by 1960
- Mechanism of action for lactamases is identical to the mechanism of inhibition for the target enzyme
- But product is removed efficiently from the lactamase active site
Problem 2 - Sensitivity to β-Lactamases

Strategy

- Use of steric shields
- Block access of penicillin to the active site of the enzyme by introducing bulky groups to the side chain
- Size of shield is crucial to inhibit reaction of penicillins with β-lactamases, but not with the target transpeptidase enzyme
Problem 2 - Sensitivity to β-Lactamases

Examples - Methicillin (Beechams - 1960)

- Methoxy groups block access to β-lactamases but not to transpeptidases
- Binds less readily to transpeptidases compared to penicillin G
- Lower activity compared to Pen G against Pen G sensitive bacteria
- Poor activity vs. some streptococci
- Inactive vs. Gram -ve bacteria
- Poor range of activity
- Active against some penicillin G resistant strains (e.g. Staphylococcus)
- Acid sensitive since there is no electron-withdrawing group
- Orally inactive and must be injected
Problem 2 - Sensitivity to $\beta$-Lactamases

Examples - Oxacillin

Oxacillin $\quad R = R' = H$

Cloxacillin $\quad R = Cl, \quad R' = H$

Flucloxacillin $\quad R = Cl, \quad R' = F$

- Orally active and acid resistant
- Resistant to $\beta$-lactamases
- Active vs. *Staphylococcus aureus*
- Less active than other penicillins
- Inactive vs. Gram -ve bacteria
- Nature of $R$ & $R'$ influences absorption and plasma protein binding
- Cloxacinilin better absorbed than oxacillin
- Flucloxacillin less bound to plasma protein, leading to higher levels of free drug
Lecture 2
27th February (12th March)
10:30 - 12:30

AlNoor University College
Pharmacy Department
2nd Course/ 4th Class
2022/2023
Teachers can open the door, but you must enter it yourself.

CHINESE PROVERB
Problem 3 - Range of Activity

Factors
1) Cell wall may have a coat preventing access to the cell
2) Excess transpeptidase enzyme may be present
3) Resistant transpeptidase enzyme (modified structure)
4) Presence of β-lactamases
5) Transfer of β-lactamases between strains
6) Efflux mechanisms

Strategy
• The number of factors involved make a single strategy impossible
• Use trial and error by varying R groups on the side chain
• Successful in producing broad spectrum antibiotics
• Results demonstrate general rules for broad spectrum activity.
Problem 3 - Range of Activity

Results of varying R in Pen G

1) Hydrophobic side chains result in high activity vs. Gram +ve bacteria and poor activity vs. Gram -ve bacteria
2) Increasing hydrophobicity has little effect on Gram +ve activity but lowers Gram -ve activity
3) Increasing hydrophilic character has little effect on Gram +ve activity but increases Gram -ve activity
4) Hydrophilic groups at the a-position (e.g. NH$_2$, OH, CO$_2$H) increase activity vs Gram -ve bacteria
Problem 3 - Range of Activity

Examples of Broad Spectrum Penicillins

Class 1 - NH$_2$ at the $\alpha$-position
Ampicillin and amoxicillin (Beechams, 1964)

Ampicillin (Penbritin)
2nd most used penicillin

Amoxicillin (Amoxil)
Problem 3 - Range of Activity

Examples of Broad Spectrum Penicillins

Properties
• Active vs Gram +ve bacteria and Gram -ve bacteria which do not produce β-lactamases
• Acid resistant and orally active
• Non toxic
• Sensitive to β-lactamases
• Increased polarity due to extra amino group
• Poor absorption through the gut wall
• Disruption of gut flora leading to diarrhea
• Inactive vs. Pseudomonas aeruginosa
Problem 3 - Range of Activity

Prodrugs of Ampicillin (Leo Pharmaceuticals - 1969)

Properties

• Increased cell membrane permeability
• Polar carboxylic acid group is masked by the ester
• Ester is metabolised in the body by esterases to give the free drug
Problem 3 - Range of Activity

Mechanism of prodrug activation

- Extended ester is less shielded by the penicillin nucleus
- Hydrolysed product is chemically unstable and degrades
- Methyl ester of ampicillin is not hydrolysed in the body
- Bulky penicillin nucleus acts as a steric shield for methyl ester
Problem 3 - Range of Activity

Examples of broad spectrum penicillins

Class 2 - CO₂H at the a-position (carboxypenicillins)

Examples

• Carfecillin = prodrug for carbenicillin
• Active over a wider range of Gram -ve bacteria than ampicillin
• Active vs. *Pseudomonas aeruginosa*
• Resistant to most b-lactamases
• Less active vs Gram +ve bacteria (note the hydrophilic group)
• Acid sensitive and must be injected
• Stereochemistry at the a-position is important
• CO₂H at the a-position is ionised at blood pH
Problem 3 - Range of Activity

Examples of broad spectrum penicillins

Class 2 - CO$_2$H at the a-position (carboxypenicillins)

Examples

- Administered by injection
- Identical antibacterial spectrum to carbenicillin
- Smaller doses required compared to carbenicillin
- More effective against *P. aeruginosa*
- Fewer side effects
- Can be administered with clavulanic acid
Problem 3 - Range of Activity

Examples of broad spectrum penicillins

Class 3 - Urea group at the a-position (ureidopenicillins)

Examples
- Azlocillin
- Mezlocillin
- Piperacillin

- Administered by injection
- Generally more active than carboxypenicillins vs. streptococci and *Haemophilus* species
- Generally have similar activity vs Gram -ve aerobic rods
- Generally more active vs other Gram -ve bacteria
- Azlocillin is effective vs *P. aeruginosa*
- Piperacillin can be administered alongside tazobactam
Penicillin G (benzylpenicillin)
Penicillin V (phenoxymethylpenicillin)

The hydrophobic character of Penicillin V is directly related to the binding to plasma proteins, renal elimination: (competition with probenecid, or diuretic), therefore their half-life increased.
Administrable orally, narrow antibacterial spectrum, limited to Gram + germs.
Indications:

➢ Penicillin G: infections caused by susceptible germs ENT / pulmonary / soft tissue
➢ Penicillin V: streptococcal infections

Adverse effects: especially allergic.

B. Semisynthetic penicillins

We want molecules that can be used orally, slowly eliminated, resistant to Beta-lactamases, with a broad spectrum and shifted to Gram-negative bacteria.
Classification of synthetic penicillins

1 **Penicillins G** (benzylpenicillin) and **V** (phenoxyethylpenicillin): sensitive to penicillinases, penicillin V is resistant to acid hydrolysis **oral** route.

2. **Group M** penicillins: narrow spectrum, resistant to penicillinases (hindered penicillins), isoxazolopenicillins (oxacillin, cloxacillin).

3. **Group A** penicillins (aminopenicillins): **spectrum** broadened and shifted to **Gram** - bacteria, **orally active**.
   - **Ampicillin** (and combination Sulbactam)
   - **Pro--ampicillins** characterized by better pharmacokinetics: pivampicillin, bacampicillin
   - **Ampicillin analog**: amoxicillin (and a combination of clavulanic acid)

4. **Ureidopenicillins**: mezlocillin, piperacillin (and combination with tazobactam).
HEMISYNTHETIC BETA LACTAMS

5. Carboxypenicillins: antipyocyanics (anti *Pseudomonas aeruginosa*), Ticarcillin (and Associate with clavulanic acid).


**Access routes to penicillins**

1. *Natural penicillins*: by fermentation of selected strains of *Penicillium notatum, P. chrysogenum* with addition of precursors:
   - Phenylacetic acid → penicillin G
   - Phenoxyacetic acid → penicillin V

2. Hemisynthetic penicillins: acylation of 6-aminopenicillanic acid (6-APA) obtained enzymatically (bacterial or fungal amidases).
Penicillins M

The more crowded the molecule, the more it is protected from beta lactamases, this is the steric shield.

Narrow spectrum, sterically hindered, resistant to penicillinases and therefore effective on *Staphylococcus aureus*, which produces penicillinase. Less effective than natural penicillins on strains that do not produce penicillinases. Oral or parenteral route at a dose of 2 to 3 g / d and more.
Therapeutic benefit: **infections with Staphylococcus aureus** producing resistant and sensitive penicillinases, methicillin.

5. **Group A penicillins (aminopenicillins)**

Hydrophilic molecules capable of crossing porins, broad spectrum, active on Gram - bacteria but inactive on staphylococci producing penicillinases. Orally active (stable in acidic medium: amine).

5.1 **Aminopenicillins: Ampicillin**

Used as trihydrate and sodium salt trihydrate.

**Antibacterial spectrum:**

active on many Gram germs -, but frequent resistance (Klebsiella, Enterobacter, Serratia, Pseudomonas aeruginosa, Bacteroides fragilis ...)

![Chemical structure of Ampicillin]

(3R,5R,6R)
Pharmacokinetic data:
• Better tissue diffusion (CSF)
• Urinary and biliary elimination (10 - 20% dose)
• low bioavailability (40%)
• Better duration of action than penicillin G (t1 / 2 = 1h)
• Binding to plasma proteins (20%)

Therapeutic indication: especially urinary and pulmonary. Dosage: 2 - 4 g / d orally, up to 12 g / d intravenously in severe infections.

5.2. Prodrugs / Pro-ampicillins
✓ Characterized by better pharmacokinetics.
✓ obtained by protection of the amine functions:
Protection of acid functions (esters):

<table>
<thead>
<tr>
<th></th>
<th>D.C.I.</th>
<th>ND</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-CH₂-O-CO-C(CH₃)₃</td>
<td>pivampicillin</td>
<td>Pro-ampi®</td>
</tr>
<tr>
<td>CH₃</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-CH-O-CO-OC₂H₅</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Very good bioavailability (90 - 100%), higher plasma levels.
Dosage: 1 - 3 g / day
Structural analogues of ampicillin:
amoxicillin We added a phenol group which is polar.

Therapeutic use of group A
• Gram-germ infections: ENT, bronchopulmonary, urogenital, surgical ...
• In association with aminoglycosides and macrolides: septicemia, meningitis, endocarditis.
• Rashes of maculopapular erythema type, quite frequent.
5.3. Structural analogues of ampicillin: amoxicillin We added a phenol group which is polar.

5.4; Therapeutic use of group A

- **Gram-germ infections**: ENT, bronchopulmonary, urogenital, surgical ...
- In association with aminoglycosides and macrolides: septicemia, meningitis, endocarditis.
- Rashes of maculopapular erythema type, quite frequent.
Ureidopenicillins
- Benzyl C carrying a ureide group linked to a heterocycle.
- Spectrum extended to Gram germs - resistant to group A.
- Diffusion in the cerebro spinal fluid.
- Intravenous administration.

![Chemical structures of Ureidopenicillins](image-url)
Useful antibacterial activity: spectrum of ampicillin and *Serratia*, *Enterobacter*, *Citrobacter*, *Pseudomonas aeruginosa* but inactivated by *penicillinases* (and not by cephalosporinases).

Main indications: **first-line in severe infections outside hospital**, localized or generalized, mono or plurimicrobial, in monotherapy or in combination (septicemia, pneumopathies, meningitis, abdominal, urogenital, pelvic infections, etc.) with sensitive germs (in particular *Gram bacilli* - and *anaerobes*).
Dosage: 6 to 15 g / day.
In combination with tazobactam Tazocilline®.
**Carboxypenicillins** P-C incompatible acid molecules with aminoside solutions. Water soluble, hygroscopic powders, **unstable** solutions.

**PHYSICO-CHEMICAL CHARACTERISTICS**

✓ powders soluble in water (disodium salt), hygroscopic,
✓ unstable solutions (a few hours in in an acidic environment),
✓ P-C incompatibilities with amino side solutions.

**Indications**: reserved for serious infections with Gram-resistant bacteria including *Pseudomonas aeruginosa* and *Proteus-R* and anaerobic Gram + bacteria.

Dosage: 5 - 20 g / d every 8 hours.
Combination with clavulanic acid Claventin®, Augmentin®
Amidinopenicillins Narrow spectrum, limited to certain Enterobacteriaceae, loss of activity against Gram + bacteria, treatment of lower urinary tract infections with sensitive Enterobacteriaceae.

<table>
<thead>
<tr>
<th>R</th>
<th>D.C.I.</th>
<th>ND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na⁺</td>
<td>mecillinam</td>
<td></td>
</tr>
<tr>
<td>CH₂-O-CO-C(CH₃)₃ (HCl)</td>
<td><strong>pivmecillinam</strong></td>
<td><strong>Selexid®</strong></td>
</tr>
</tbody>
</table>

✓ Narrow spectrum, limited to certain Enterobacteriaceae,
✓ loss of activity on Gram + germs
✓ treatment of lower urinary tract infections caused by sensitive enterobacteriaceae.
Organic Pharm. Chemistry III

Lecture 8
3rd April 2023
10:30- 1:30

AlNoor University College
Pharmacy Department
2nd Course/ 4th Class
2022/2023
“Yesterday I was clever, so I wanted to change the world. Today I am wise, so I am changing myself.”

Rumi
Introduction

Sulfonamides (Sulphonamides) are a group of man-made (synthetic) medicines that contain the sulfonamide chemical group. They may also be called sulfa drugs.

- Some sulfonamides are also devoid of antibacterial activity, e.g., the anticonvulsant (Sultiame). The sulfonylureas and thiazide diuretics are newer drug groups based upon the antibacterial sulfonamides.
- The first sulfonamide was trade named Prontosil, which is a prodrug Prontosil, the first commercially available antibacterial with a relatively broad effect (against Gram-positive cocci but not against enterobacteria).

Azo reduction of prontosil is one example, where intestinal bacteria convert inactive therapeutics into their pharmacologically active form. Bacterial azoreductases present in the distal gut cleave the N-N double bond and produce active metabolite sulfanilamide.
Allergies to sulfonamides are common. The overall incidence of adverse drug reactions to sulfa antibiotics is approximately 3%, close to penicillin.

- The general structure of Sulfonamides

Sir Gerhard Domagk, (born October 30, 1895, Lagow, Brandenburg, Germany-died April 24, 1964, Burgberg, near Königsfeld, Germany), German bacteriologist and pathologist who was awarded the 1939 Nobel Prize for Physiology or Medicine for his discovery (announced in 1932) of the antibacterial effects of Prontosil, the first of the sulfonamide drugs.
• Trimethoprim exerts a synergistic effect with sulfonamides.
• - Trimethoprim is often given in combination with sulfamethoxazole, which inhibits the preceding step in bacterial protein synthesis-given together, sulfamethoxazole and trimethoprim inhibit two consecutive steps in the biosynthesis of bacterial nucleic acids and proteins. As a monotherapy trimethoprim is considered bacteriostatic, but in combination with sulfamethoxazole is thought to exert bactericidal activity.
Mechanism of action: Sulfonamides & Trimethoprim

- Sulfanilamide is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. This enzyme normally uses para-aminobenzoic acid (PABA) for synthesizing the necessary folic acid. The inhibited reaction is normally necessary in these organisms for the synthesis of folic acid. Without it, bacteria cannot replicate.

- Trimethoprim is a reversible inhibitor of dihydrofolate reductase, one of the principal enzymes catalyzing the formation of tetrahydrofolic acid (THF) from dihydrofolic acid (DHF).

- Tetrahydrofolic acid is necessary for the biosynthesis of bacterial nucleic acids and proteins and ultimately for continued bacterial survival-inhibiting its synthesis, then, results in bactericidal activity. Trimethoprim binds with a much stronger affinity to bacterial dihydrofolate reductase as compared to its mammalian counterpart, allowing trimethoprim to selectively interfere with bacterial biosynthetic processes.
Pteridine + PABA

\[
\text{PABA} \quad \text{HOOC} \quad \text{NH}_2
\]

dihyopterote acid synthase

Dihyopteroic acid

dihydrofolate synthase

dihydrofolate reductase

Dihydrofolate acid

\[
\text{SO}_2\text{NH} \quad \text{CH}_3 \quad \text{CH}_3
\]

Sulfisoxazole

\[
\text{NH}_2
\]

Trimethoprim

Para-aminobenzoic acid + pteridine

\[
\text{GTP}
\]

Sulfonamides

Competitive inhibition

Dihyopteroic acid

L-Glutamate

Dihydrofolate synthetase

Dihydrofolate acid

2 \text{NADPH}

Dihydrofolate reductase

2 \text{NADP}^+

Tetrahydrofolate acid

Cofactors

Thymidine

DNA

DNA, RNA

Purines

Methionine

tRNA, proteins

4-Aminobenzoic acid (PABA)

Tetrahydrofolic acid

Folic acid metabolism

Folic acid
Absorption, Distribution, Metabolism & Excretion

- Sulfonamides class of drugs is absorbed rapidly from the GI tract.
- Approximately 70-100% of an oral dose is absorbed, and sulfonamide can be found in the urine within 30 min of ingestion.
- Peak plasma levels are achieved in 2-6 h, depending on the drug.
- The small intestine is the major site of absorption, but some of the drug is absorbed from the stomach. Absorption from other sites, such as the vagina, respiratory tract, or abraded skin, is variable and unreliable.
- All sulfonamides are bound in varying degree to plasma proteins, particularly to albumin.
- Sulfonamides are metabolized in the liver. The major metabolite is the N-acetylated sulfonamide. Acetylation results in products that have no antibacterial activity but retain the toxic potential of the parent substance.
Sulfonamides are eliminated from the body partly as the unchanged drug and partly as metabolic products. The largest fraction is excreted in the urine, and the $t_{1/2}$ depends on renal function.

- In acid urine, the older sulfonamides are insoluble and crystalline deposits may form. Small amounts are eliminated in the feces, bile, milk, and other secretions.
Side effects

- Sulfonamides have the potential to cause a variety of untoward reactions, including urinary tract disorders, haemopoietic disorders, and hypersensitivity reactions.

- When used in large dose, it may develop a strong allergic reaction. One of the most serious is *Stevens Johnson syndrome* (or toxic epidermal necrolysis).

- Some of the original sulfonamide drugs were derived from azo dyes and had the interesting effect of temporarily turning the patient red.

- **N.B-** *Stevens-Johnson syndrome* (SJS) is a life-threatening condition affecting the skin, in which due to cell death the epidermis separates from the dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.
Adverse reactions

i) The most common manifestation of a hypersensitivity reaction to sulfa drugs are rash and hives. However, there are several life-threatening manifestations of hypersensitivity to sulfa drugs, including Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, hemolytic anemia, thrombocytopenia, and fulminant hepatic necrosis, among others.

ii) The sulfonamide antibiotic chemical structures are implicated in the hypersensitivity reactions associated with the class.

- The first is the **N.heterocyclic ring**, which causes a type I hypersensitivity reaction.

- The second is the **N.amino nitrogen** that, in a stereospecific process, forms reactive metabolites that cause either direct cytotoxicity or immunologic response.

➢ Note By:

- **Folic acid**: Folic acid and folate (the anion form) are forms of the water-soluble Vitamin B9. These occur naturally in food and can also be taken as supplements. Folate gets its name from the Latin word folium.
• **Biological roles of folate**
  
  i) Folate is necessary for the production and maintenance of new cells. This is especially important during periods of rapid cell division and growth such as infancy and pregnancy. Folate is needed to synthesize DNA bases (most notably thymine, but also purine bases) needed for DNA replication. Thus folate deficiency hinders DNA synthesis and cell division, affecting most notably bone marrow and cancer, both of which participate in rapid cell division.

  ii) In the form of a series of tetrahydrofolate (THF) compounds, folate derivatives are substrates in a number of single-carbon-transfer reactions, and also are involved in the synthesis of dTMP (2′-deoxythymidine-5′-phosphate) from dUMP (2′-deoxyuridine-5′-phosphate). It is a substrate for an important reaction that involves vitamin B_{12} and it is necessary for the synthesis of DNA, required for all dividing cells.
- Cells use folic acid as a single-carbon atom building block for the construction of nucleic acids and other biological molecules. Inhibition of this process **prevents growth and reproduction** but does not directly lead to **cell death**. Bacteria synthesize folic acid from 2-amino-4-oxo-6-methylpteridine diphosphate, \( p \)-aminobenzoic acid (PABA), and L-glutamic acid. Because sulfa drugs are structural mimics of PABA they may bind to dihydropteroate synthetase, one of the enzymes necessary for folic acid synthesis (reversible and competitive inhibition). With this enzyme inhibited, folic acid synthesis is prevented, and cell growth and reproduction are halted.
In addition, the two molecules are of nearly identical length (6.7 Å for PABA versus 6.9 Å for sulfanilide), both are roughly flat, and both have an equal distribution of charge (δ+ on the NH₂ group and δ- on the COOH or SO₂NHR groups). This effect can be seen more clearly by examining the electrostatic potential surfaces of these molecules.
Why bacterial dihydrofolate reductase is many times more sensitive to Trimethoprim than is equivalent enzyme in humans?

- In microorganism human one of the key enzymes dihydrofolate reductase which reduces dihydrofolate to tetrahydrofolate is many more sensitive to folate antagonist trimethoprim in bacteria than in human because of IC$_{50}$ values (the concentration causing 50% inhibition).
The major features of SAR of sulphonamides include the following:
- Sulphanilamide skeleton is the minimum structural requirement for antibacterial activity.
- The amino- and sulphonyl-groups on the benzene ring are essential and should be in 1 and 4 position.
The N-4 amino group could be modified to be prodrugs, which are converted to free amino function in-vivo.
Sulphur atom should be directly linked to the benzene ring.
- Replacement of benzene ring by other ring systems or the introduction of additional substituents on it decreases or abolishes its activity.
- Exchange of the $\text{–SO}_2\text{NH}$ group by $\text{–CONH}$ reduces the activity.
- On N-1-substituted sulphonamides, activity varies with the nature of the substituent at the amino group. With substituents imparting electron-rich characters to $\text{SO}_2$ group, bacteriostatic activity increases.
Heterocyclic substituents lead to highly potent derivatives, while sulphonamides, which contain a single benzene ring at **N-1 position**, are considerably more toxic than heterocyclic ring analogues.

- The free aromatic amino groups should reside para to the sulphonamide group. Its replacement at ortho or meta position results in compounds devoid of antibacterial activity.

- The active form of sulphonamide is the ionized, maximum activity that is observed between the pKa values **6.6–7.4**.

- Substitutions in the benzene ring of sulphonamides produced inactive compounds.

- Substitution of free sulphonic acid (\(–\text{SO}_3\text{H}\)) group for sulphonamido function destroys the activity, but replacement by a sulphinic acid group (\(–\text{SO}_2\text{H}\)) and acetylation of **N-4** position retains back the activity.

- **Meta-Sulphonamides** bind to the basic centres of arginine, histidine, and lysine sites of proteins. The binding groups are alkyl, alkoxy, and halides. The binding affects the activity of sulphonamides; protein binding appears to modulate the availability of the drug and its half-life.

- The lipid solubility influences the pharmacokinetic and antibacterial activity, and so increases the half-life and antibacterial activity in vitro.
Sulphonamides can be classified on the basis of the chemical structure

- (i) **N-1 substituted sulphonamide**: Sulphadiazine, Sulphacetamide, Sulphadimidine.
- (ii) **N-4 substituted sulphonamides (prodrugs)**: Prontosil.
- (iii) **Both N-1 and N-4 substituted sulphonamides**: Succinyl sulphathiazole, Phthalylsulphathiazole.
- (iv) **Miscellaneous**: Mefenide sodium.
### N-1 Substituted Sulphonamides

<table>
<thead>
<tr>
<th>Name</th>
<th>R</th>
<th>R′</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulphanilamide</td>
<td>−H</td>
<td>−H</td>
</tr>
<tr>
<td>Sulphacetamide</td>
<td>−H</td>
<td>−COCH₃</td>
</tr>
<tr>
<td>Sulphadiazine</td>
<td>−H</td>
<td>−</td>
</tr>
<tr>
<td>Sulphamethoxazole</td>
<td>−H</td>
<td>[structure]</td>
</tr>
</tbody>
</table>

### N-4 Substituted Sulphonamides

- Prontosil
- Mafenide

### N-1 and N-4 Substituted Sulphonamides

<table>
<thead>
<tr>
<th>Name</th>
<th>R</th>
<th>R′</th>
</tr>
</thead>
<tbody>
<tr>
<td>Succinyl Sulphathiazole</td>
<td>−CH₂O −</td>
<td>−CH₂ −</td>
</tr>
<tr>
<td>Phthalyl Sulphathiazole</td>
<td>−O −</td>
<td>−HO −</td>
</tr>
</tbody>
</table>

- Silver Sulphadiazine
- Trimethoprim
• **Dapsone (DDS, Diaminodiphenyl sulphone)**

**Mechanism of action**
- As an antibacterial, Dapsone inhibits bacterial synthesis of **dihydrofolic acid**, via competition with **para-aminobenzoate** for the active site of **dihydropteroate synthase**.
- As an anti-inflammatory, Dapsone inhibits the enzyme **myeloperoxidase**. As part of the respiratory burst that neutrophils use to kill bacteria.
Adverse effects

The most prominent side-effects of this drug are dose-related hemolysis (which may lead to hemolytic anemia) and methemoglobinemia.
- Toxic hepatitis and cholestatic jaundice.
- Other adverse effects include nausea, headache, and rash (which are common), and insomnia, psychosis, and peripheral neuropathy.

• Dosage
- The dose as tablets is 25 or 100 mg. For adults the dose consumed is 50 mg per day orally. For lepromatous leprosy, 100 mg Dapsone + 600 mg Rifampin and/or clofazimine 100 mg daily for at least 2 years followed by Dapsone monotherapy.
For borderline tuberculoid disease,
Dapsone 100 mg daily + Rifampin 600 mg once monthly for 6 months.
Pharmacokinetics

- The major metabolic product of Dapsone results from **N-acetylation** in the liver by **N-acetyltransferase**.
- It also undergoes **N-hydroxylation** to **hydroxylamine derivative**. These metabolic reactions are catalyzed by **CYP3A4** isoforms.
- The urine consists of small amounts of Dapsone and the metabolites, that is, **N-acetyl-diamino-diphenyl sulphone** and **N-hydroxy-diamino-diphenyl sulfone**, as well as glucuronide and sulphate of each of these substances.
- Dapsone is commonly used in combination with rifampicin and clofazimine for the treatment of leprosy.
- It is also used to both treat and prevent pneumocystis pneumonia and toxoplasmosis.
- Dapsone by mouth was one of the first medications used to treat moderate to severe acne vulgaris and useful in the prevention of malaria.
- Dapsone also used to treat Autoimmune disease (like Cutaneous lupus erythematosus, Idiopathic thrombocytopenic purpura, Chronic spontaneous urticaria, Relapsing polychondritis).
- Dapsone also used in treatment of Dermatitis herpetiformis and generalized granuloma annulare.
- Dapsone has been used as a monomer in the design of dye adsorbent polymers.
Trimethoprim/Sulphamethoxazole

- Trimethoprim/Sulphamethoxazole (TMP/SMX), also known as Co-T trimoxazole.

- Co-trimoxazole is available in oral and intravenous preparations with the standard single-strength tablet containing 80 mg of trimethoprim combined with 400 mg of sulfamethoxazole.

- It is an antibiotic used to treat a variety of bacterial infections.

- It consists of one part trimethoprim to five parts sulfamethoxazole.

- It is used for urinary tract infections, skin infections, travellers’ diarrhoea, respiratory tract infections, and cholera, among others.

- It may be used both to treat and prevent pneumocystis pneumonia in people with HIV/AIDS.
Co-Trimoxazole can be used to treat or prevent:

▪ Lung infections (pneumonia or PJP) caused by a bacterium called *Pneumocystis jirovecii* (previously *P. carinii*).
▪ It is used for skin infections, travellers’ diarrhoea, and cholera.
▪ Infections caused by a bacterium called *Toxoplasma* (toxoplasmosis).
▪ An infection called nocardiosis which can affect the lungs, skin and brain.
▪ It may be used both to treat and prevent pneumocystis pneumonia in people with HIV/AIDS.

- It can be given by orally or intravenously.

- **Common side effects** include nausea, vomiting, rash, and diarrhoea.
- Severe allergic reactions and *Clostridium difficile diarrhoea* may occasionally occur.
- Its use near the end of pregnancy is not recommended.
- It appears to be safe for use during breastfeeding as long as the baby is healthy.
- TMP/SMX generally results in bacterial death. It works by blocking the making of folate by the bacteria.
• **Mechanism of Action**

```
dihydropteroate diphosphate + p-aminobenzoic acid (PABA)
```

```
dihydropteroate synthetase
```

```
dihydropteroic acid
```

```
dihydrofolate reductase
```

```
sulphonamides
```

```
trimethoprim
```

```
sulphamethoxazole
```

```
dihydrofolate reductase
```

```
tetrahydrofolate acid
```

```
trimethoprim
```

```
trimethoprim
```

```
sulphamethoxazole
```

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulphamethizole</td>
<td>Cystitis, Genital tract inflammation, Gonorrhea, Nephritis, Prostatitis, Urinary Tract Infection and Vaginal Inflammation</td>
</tr>
<tr>
<td>Sulphaisoxazole</td>
<td>Urinary Tract Infections, Meningococcal Meningitis, Acute Otitis Media, Trachoma, Inclusion Conjunctivitis, Nocardiosis, Chancroid, Toxoplasmosis, Malaria and Other Bacterial Infections.</td>
</tr>
<tr>
<td>Sulfamethazine</td>
<td>For the treatment bacterial infections causing bronchitis, prostatitis, Bacterial Conjunctivitis, Endometritis, Furuncle, Streptococcal Sore Throat, Ulcers and Urinary Tract Infections.</td>
</tr>
<tr>
<td>Sulfacetamide</td>
<td>For the treatment of Bacterial Vaginitis, Keratitis, Acute Conjunctivitis, Acne Vulgaris, Conjunctivitis, Trachoma, Superficial Ocular Infections and Blepharitis.</td>
</tr>
<tr>
<td>Sulphapyridine</td>
<td>For the treatment of Dermatitis Herpetiformis, Benign Mucous Membrane Pemphigoid and Pyoderma Gangrenosum.</td>
</tr>
<tr>
<td><strong>Sulphamethoxazole</strong></td>
<td>Sulphamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible Shigella, prophylaxis and treatment of <em>Pneumocystis jiroveci</em> pneumonia, and travelers' diarrhea caused by enterotoxigenic <em>E. coli</em>. Additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with gentamicin or rifampicin.</td>
</tr>
<tr>
<td><strong>Sulphadiazine</strong></td>
<td>For the treatment of rheumatic fever, Nocardiosis, Plague, Plasmodium Infections, Toxoplasmosis, Trachoma, Urinary Tract Infection, Wound Infections, Bacterial otitis media caused by Haemophilus influenzae, Prophylaxis of Rheumatic fever Recurrent Rheumatic fever and meningococcal meningitis.</td>
</tr>
<tr>
<td><strong>Mafenide</strong></td>
<td>Indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds (Second Degree Burns and Third-Degree Burns).</td>
</tr>
<tr>
<td><strong>Sulfasalazine</strong></td>
<td>For the treatment of Crohn's disease, Crohn's Disease (CD), Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Mild Ulcerative Colitis, Moderate Ulcerative colitis</td>
</tr>
</tbody>
</table>
Organic Pharmaceutical Chemistry II

BY:
Dr. Nohad A AlOmar (B.Pharm/MSc & PhD in Medicinal Chemistry)

Fashion is my drug
Organic Pharm. Chemistry II

Lecture 1
16th September 2023 (8:30- 11:30 )( 11:30- 2:30)

AlNoor University College
Pharmacy Department
1st Course/ 4th Class
2023/2024
Quote of Today

ALLAH MAKES THE IMPOSSIBLE POSSIBLE
Objectives: The course is devoted to the discovery and development of new agents for treating diseases, and enables translating the drug structural formula into therapeutic effect. Additionally, it focuses on the methods of preparation for some pharmaceutical agents.

<table>
<thead>
<tr>
<th>No</th>
<th>Lecture title</th>
<th>hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Cholinergic agents, cholinergic receptors and their subtypes.</td>
<td>2</td>
</tr>
<tr>
<td>2.</td>
<td>Cholinergic agonists; stereochemistry and structure-activity relationships (SAR); products; cholinesterase inhibitors.</td>
<td>5</td>
</tr>
<tr>
<td>3.</td>
<td>Cholinergic blocking agent; structure-activity relationships (SAR); Solanaceous alkaloid and analogues; synthetic cholinergic blocking agents and products; ganglionic blocking agents (neuromuscular blocking agents).</td>
<td>6</td>
</tr>
<tr>
<td>4.</td>
<td>Analgesic agents (SAR of morphine, SAR of meperidine type molecules; SAR of methadone type compounds; N-methylbezomorphans, antagonist type analgesics in benzomorphans).</td>
<td>3</td>
</tr>
<tr>
<td>5.</td>
<td>Analgesic receptors, endogenous opioids; Products; Antitusive agents; Anti-inflammatory analgesics.</td>
<td>7</td>
</tr>
<tr>
<td>6.</td>
<td>Adrenergic agents (Adrenergic neurotransmitters); Adrenergic receptors; Drugs affecting Adrenergic neurotransmission; Sympathomimetic agents; Adrenergic receptor antagonists.</td>
<td>11</td>
</tr>
<tr>
<td>7.</td>
<td>CNS depressant; Benzodiazepines and related compounds; Barbiturates; CNS depressant with skeletal muscle relaxant properties; Antipsycotics; Anticonvulsants.</td>
<td>9</td>
</tr>
</tbody>
</table>
Reference Books


Extra Reading Assignments:
Introduction:

-Definition of Cholinergic agent.
-Cholinergic receptors (Muscarinic and Nicotinic receptors); their subtypes, locations and functions.
-Synthesis, Structure activity relationship (SAR) of Acetylcholine (Ach).
that Ach is the transmitter secreted by all autonomic preganglionic nerve terminals. Hence, all synapses between pre- and post-ganglionic fibres are cholinergic.

Similarly, parasympathetic postganglionic fibres secrete Ach, i.e. synaptic junctions between parasympathetic postganglionic fibres and effector organs are also cholinergic.

By contrast, virtually all sympathetic postganglionic neurons secrete NE: Thus, synapses between sympathetic postganglionic fibres and effectors are adrenergic. Note that there are some exceptions to this latter rule: Sympathetic postganglionic fibres innervating certain sweat glands (eccrine glands) secrete Ach, as do some of the sympathetic postganglionic fibres controlling blood vessel dilatation in skeletal muscle.
To Summarize:

<table>
<thead>
<tr>
<th>Type of axon</th>
<th>Transmitter</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preganglionic-symp + parasymp.</td>
<td>Ach</td>
<td>Exc. only</td>
</tr>
<tr>
<td>Postganglionic-symp. (most)</td>
<td>NE</td>
<td>Exc./Inhib.</td>
</tr>
<tr>
<td>Postganglionic-symp. (some)</td>
<td>Ach</td>
<td>Exc./Inhib.</td>
</tr>
<tr>
<td>Postganglionic-parasymp.</td>
<td>Ach</td>
<td>Exc./Inhib.</td>
</tr>
</tbody>
</table>

GNS = central nervous system; Pre = preganglionic; Post = postganglionic; ACh = acetylcholine; N = nicotinic receptor; NE = norepinephrine; EPI = epinephrine; D = dopamine; M = muscarinic receptor; β = β-adrenoceptor; α = α-adrenoceptor; D1 = dopaminergic receptor
Pharmacological effects of Ach

A) Through the muscarinic receptor

Cardiac effects
- Bradycardia,
- decrease of atrioventricular conduction.
- decrease of the strength of atrium contractions.

Blood vessels
- Acetylcholine injection causes release of nitric oxide (NO) which dilates blood veins

- Effects on smooth muscles
  - intestine: an increase in tone with sometimes an increase in the peristaltic contractions. This can lead to Nausea and vomiting.
  - ureters: increase in tone.
  - bronchi: bronchoconstriction. (An aerosol of acetylcholine can cause an attack of asthma)

- Effects on secretions
  - Acetylcholine increases digestive (abundant saliva), bronchial, cutaneous (sweat) and lacrimal (tears) secretions.

- Effects on the eye
  - Acetylcholine induces a decrease of iris diameter or miosis which can lower the intra-ocular pressure

- Through the nicotinic receptor
  - In Autonomic NS, Ach allows nerve transmission
  - In neuromuscular junctions
    - At low dose Ach allow skeletal muscle movement (important for breathing)
    - At high does, it causes muscle paralysis!
  - In Brain, cholinergic deficiency causes Alzheimer disease
Autonomic nervous system

The component of the CNS (Central Nervous System) that functions below the conscious level, controlling several key physiological processes:
1. Distribution of blood flow & tissue perfusion
2. Regulation of blood pressure
3. Control of visceral smooth muscle (eyes, bladder, bowels)
4. Control of endocrine and exocrine glands
5. Control of metabolic energy (glycolysis, neoglucogenesis etc)

Biologic responses to parasympathetic stimulation:
• Constriction of pupil (miosis), ciliary body (“accommodation” of lens)
• Contraction of smooth muscle in the GI (“peristalsis”) and urinary tract
• Constriction of the bronchioles (“broncho constriction”)
• Slowing of heart rate (“bradycardia”)
• Increased secretion by the gland
The component of the CNS (Central Nervous System) that functions below the conscious level, controlling several key physiological processes:

1. Distribution of blood flow & tissue perfusion
2. Regulation of blood pressure
3. Control of visceral smooth muscle (eyes, bladder, bowels)
4. Control of endocrine and exocrine glands
5. Control of metabolic energy (glycolysis, neoglucogenesis etc)

Biologic responses to parasympathetic stimulation:

- Constriction of pupil (miosis), ciliary body (“accommodation” of lens)
- Contraction of smooth muscle in the GI (“peristalsis”) and urinary tract
- Constriction of the bronchioles (“broncho constriction”)
- Slowing of heart rate (“bradycardia”)
- Increased secretion by the gland
Muscarinic Receptors

Acetylcholine is the transmitter at three different sites, autonomic ganglia, parasympathetic postganglionic nerve terminals and skeletal muscle motor nerve terminals.

The action of acetylcholine on visceral effectors (smooth muscle of GIT, cardiac muscle and exocrine gland) resembles the action of the naturally occurring plant alkaloid muscarine. Therefore these receptors of acetylcholine on visceral effectors are called muscarinic receptors.

Atropine blocks this receptor of acetylcholine. Acetylcholine in large dose exhibits its effects through ganglionic stimulation.

This response resembles the effect of naturally occurring alkaloid nicotine. Thus, the response of acetylcholine on parasympathetic ganglia, sympathetic ganglia and adrenal medulla and neuromuscular junction are called nicotinic receptors.

At the skeletal muscle motor plate the cholinergic receptors are nicotinic in nature; d-tubocurarine blocks these receptors in the skeletal muscle. The ganglionic nicotinic receptors are blocked by hexamethonium.
Parasympathetic Ganglionic Synapse

Preganglionic neuron

Postganglionic neuron

Action Potential

Na$^+$

Ca$^{2+}$

Acetylcholinesterase

Nicotinic Receptor

ACH

Acetylcholine
Parasympathetic Organ Synapse

Postganglionic neuron

Action Potential

\( \text{Na}^+ \)

\( \text{Ca}^{2+} \)

Acetylcholinesterase

Effector Organ

K^+

Muscarinic Receptor

\( \text{ACH} \)
Sympathetic Ganglionic Synapse

Preganglionic neuron

Postganglionic neuron

Action Potential

Na$^+$

Ca$^{2+}$

Acetylcholinesterase

Nicotinic Receptor

ACH
Muscarinic receptor (M); mitogen-activated protein kinase (MAPK or MAP kinase); Phospholipase C (PLC); G-Protein-Coupled Inwardly Rectifying Potassium (GIRK)

Subclassification of mAch receptors
### Muscarinic receptors subtypes and functions

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Tissue location</th>
<th>Function</th>
</tr>
</thead>
</table>
| M1       | CNS, gastric and salivary glands, autonomic ganglia, enteric nerves | ↑ Cognitive function  
↑ Seizure activity, ↑ Secretions  
↑ Autonomic ganglia depolarization  
↓ DA release and locomotion |
| M2       | Autonomic nerve terminals; CNS; heart; smooth muscle | ↑ Smooth muscle contraction  
Neural inhibition in periphery via autoreceptors and heteroreceptor  
↓ Ganglionic transmission  
Neural inhibition in CNS, ↓ Heart rate  
↑ Tremors hypothermia & analgesia |
| M3       | CNS (< other mAChRs), smooth muscle, glands, heart | ↑ Smooth muscle contraction (e.g., bladder)  
↑ Salivary gland secretion  
↑ Food intake, body fat deposits  
Inhibits dopamine release  
Synthesis of nitric oxide |
| M4       | CNS | Inhibition of autoreceptor- and heteroreceptor-mediated transmitter release in CNS, Analgesia, Cataleptic activity;  
Facilitates dopamine release |
| M5       | Low levels in CNS & periphery; predominate mAChRs in dopaminergic neurons of substantia nigra & ventral tegmentum area | Mediates dilation of cerebral arteries  
Facilitates dopamine release  
Augments drug seeking behavior and reward |
## Nicotinic receptors subtypes and functions

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Location</th>
<th>Membrane Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skeletal muscle (N_m) (α_1β_2δ)</td>
<td>Skeletal neuromuscular junction (post-junctional)</td>
<td>Excitatory; end plate depolarization; contraction (skeletal muscle)</td>
</tr>
<tr>
<td>Peripheral neuronal (N_n) (α_3δ)(β_4)_3</td>
<td>Autonomic ganglia; adrenal medulla</td>
<td>Excitatory; depolarization firing of postganglionic neuron; depolarization &amp; secretion of catecholamines</td>
</tr>
<tr>
<td>Central neuronal (CNS) (α_4)(β_4)_3 (α-bungarotoxin insensitive)</td>
<td>CNS; pre- &amp; postsynjctional</td>
<td>Pre- &amp; postsynaptic excitation; prejunctional control of transmitter release</td>
</tr>
<tr>
<td>(α_7)_5 (α-bungarotoxin sensitive)</td>
<td>CNS; pre- and postsynaptic</td>
<td>Same as central neuronal</td>
</tr>
</tbody>
</table>

- They are agonized by nicotine
- They also occur in the CNS and Autonomic NS plus are exclusive in neuromuscular junction, and are part of a ligand gated ion channel receptors
- Physiological functions depend upon muscle-type or neuronal-type
- Muscle-type nicotinic AChRs are localized at neuromuscular junctions and allow muscle contraction and maintain muscle tone; *(thus these are targets for muscle relaxants)*
- Neuronal type are involved in cognitive function, learning and memory, arousal, reward, motor control and analgesia.
Muscarinic Receptors Vs Nicotinic Receptors
Muscarinic Receptors Vs Nicotinic Receptors

1. **Muscarinic receptors**
   - Activates cholinergic receptors on smooth muscle and cardiac muscle

2. **Nicotinic receptors**
   - Activates cholinergic receptors at nerve synapses and on skeletal muscle
Biosynthesis & Hydrolysis of Acetylcholine

Biosynthesis of Acetylcholine:

l-Serine

Serine Decarboxylase → HO-CH₂-NH₂
Choline-N-Methyl-Transferase → S-Adenosylmethionine (Me donor)

Choline

Choline Acetyl Transferase → Acetyl-S-Coenzyme A (Acetyl donor)

Acetylcholine

Hydrolysis of Acetylcholine:

Acetylcholine Esterase (AChE) → HO-CH₂-NH₂

Acetylcholine

Choline

Acetate
Hydrolysis of Ach

Acid catalyzed hydrolysis of Ach

Base catalyzed hydrolysis of Ach
Several quaternary ammonium bases act as competitive inhibitors of choline uptake. Hemicholinium(HC-3), bisquaternary cyclic hemiacetal, and triethyl analogue of choline, 2-hydroxyethyltriethylammonium, act at the presynaptic membrane to inhibit the high affinity uptake of choline into the neuron (1). Cause a delayed paralysis at repetitively activated cholinergic synapse and can produce respiratory paralysis in test animals. The delayed block is caused by the depletion of stored Ach, which may be reversed by choline.
• **Chemistry**

  Acetylcholine is a choline molecule that has been acetylated at the oxygen atom. Because of the charged ammonium group, acetylcholine does not penetrate lipid membranes. Because of this, when the molecule is introduced externally, it remains in the extracellular space and at present it is considered that the molecule does not pass through the blood–brain barrier.

  ![Chemical structures](image)

• **Stereochemistry of Ach:-**

  Early models for cholinergic receptor did not account for the observed stereo selectivity of the receptor for agonist and antagonist.

  Even though Ach does not exhibit optical isomerism but many synthetic & naturally occurring agonists and antagonists are optical isomers.

  One of the enantiomer is many times more active than other. Thus the stereochemistry of cholinergic ligands is important for receptor binding.

  The stereochemistry of cholinergic ligands provides rational basis for design of cholinergic drugs as well as to describe properties and function of cholinergic receptors.
Conformations of Ach

Separation between ester and quaternary nitrogen groups is important for binding. This distance is different in Muscarinic and nicotinic receptors.

ACTM: 2-acetoxy-cyclopropyl-1-trimethylammonium

Muscarinic receptor

Nicotinic receptor
Acetylcholine is not used in clinical practice why??
because:
1. It is very toxic
2. The doses required are very high
3. It is very rapidly hydrolyzed
4. It is very costly
STRUCTURE ACTIVITY RELATIONSHIP

- Acetylcholine can exist in a number of conformations. Four of these conformations are synplanar, synclinal, anticlinal, and antiplanar.
- The most active isomer is the (+) trans enantiomer and it is identical to synclinal conformation of acetylcholine.
- The muscarinic receptors and acetylcholinesterase display stereoselectivity, the (S) enantiomer of methacholine is equipotent with acetylcholine, while the R (−) enantiomer is about 20-fold less potent.
I. Modification of Quaternary Ammonium Group

The quaternary ammonium group is essential for intrinsic activity, and contributes to the affinity of the molecule for the receptors, partially through the binding energy and partially because of its action as a detecting group.

The trimethyl ammonium group is the optimal functional moiety for the activity, although some exceptions are known (e.g. pilocarpine, nicotine, and oxotremorine), and it shows maximal muscarinic activity.

Placement of primary, secondary, or tertiary amines leads to decrease in activity.

II. Modification of acyloxy group

The ester group of ACh contributes to the binding of the compound to the muscarinic receptor.

Replacement of methyl group by ethyl or large alkyl groups produces inactive compounds. Esters of aromatic or higher molecular weight acids possess cholinergic antagonist activity.
III. Modification of ethylene bridge

The methyl ester is rapidly hydrolyzed by cholinesterase to choline and acetic acid. To reduce susceptibility to hydrolysis, carbamate esters of choline (carbachol) were synthesized and were found to be more stable than carboxylate esters.

Placement of α-substitution in choline moiety results in a reduction of both nicotinic and muscarinic activity, but muscarinic activity to a greater extent.

Incorporation of β-substitution leads to reduction of nicotinic activity to greater extent.

Replacement of ester group with ether or ketone produces chemically stable and potent compounds.

Replacement of acetyl function gives rise to agonist, partial agonist, or antagonist [please see the size and the nature of the functional group replacement]

III. Modification of ethylene bridge

Muscarinic agonist
S(+) 240 X more active than R(-) isomer

Nicotinic agonist

inactive
(both muscarinic or nicotinic)

β methyl substitution produces selective muscarinic agonist
α methyl substitution produces selective nicotinic agonist

Methacholine
S(+) 240 X more active than R(-) isomer

Nicotinic agonist

inactive
(both muscarinic or nicotinic)
**Outlines of SAR of ACh**

**Acyloxy group**
The molecule should have an oxygen atom, preferably an ester-like oxygen capable of participating in a hydrogen bond.

**Ethylene group**
There should be a two-carbon units between the oxygen atom and the nitrogen atom.

**Quaternary amine group**
A molecule must possess a nitrogen atom capable of bearing a positive charge, preferably a quaternary ammonium salt.

For maximum potency, the size of the alkyl groups substituted on the nitrogen should not exceed the size of a methyl group.

**Inclusion of methyl group in beta carbon to N makes muscarinic selective**

**Inclusion of methyl group in beta carbon to N makes Nicotinic selective**

The overall size of the molecule cannot be altered, much bigger molecules have poorer activity.

A larger third alkyl group is tolerated but more than one large alkyl groups leads to loss of activity.
Cholinergic Agonists

**Acetylcholine chloride**
- Prototypical muscarinic (and nicotinic) agonist, but a poor therapeutic agent.
- Chemical/ enzymatic instability; Low bioavailability (poorly absorbed); Nonselective action.
- Quick onset and short duration of action.
- **Use:** In ocular surgery, causes complete miosis in seconds. Instilled directly in the anterior chamber.

**Methacholine chloride**
- More stable than acetylcholine.
- More selective action (muscarinic > nicotinic).
- Racemic drug. $S$-enantiomer more active.

**Carbachol chloride**
- Potent agonist activity. Nonselective (Muscarinic / Nicotinic)
- Also acts indirectly by promoting ACh release and anticholinesterase (weak) activity.
- Increased hydrolytic stability (carbamate linkage more stable than ester)
- **Uses:** Topically for glaucoma; intraocular for miosis in surgery
- **Side Effects:** Corneal edema; decreased vision.

**Bethanechol chloride**
- Potent muscarinic agonist. Orally effective, also administered by subcutaneous injection.
- Increased hydrolytic stability (carbamate and steric bulk)
- Stimulant of GI tract smooth muscle and urinary bladder.
- **Uses:** For the relief of post-surgical urinary retention and abdominal distention.
- **Low toxicity, no serious side effects.** Should be used with caution in asthmatic patients.
Pilocarpine

- Natural product. Isolated from the leaves of *Pilocarpus jaborandi*.
- Unstable to alkali (lactone hydrolysis) and bases (epimerization at C-3).
- Available as ophthalmic solution, gel, tablet and Ocusert delivery system.
- Systemic effects include copious sweating, salivation and gastric secretion.
- Used in the treatment of glaucoma and xerostomia (dry mouth).
Future Muscarinic Agonists:

Current research interest is focused on developing agents with selective affinity for muscarinic receptors in the brain. Potentially useful in the treatment of Alzheimer’s disease and other cognitive disorders.
Requisitions for Lec. 2
(( classification of cholinergic drugs, introduction to anticholinergic Drugs ))
Organic Pharm. Chemistry II

Lecture 2
30th September 2023 (8:30-11:30) (11:30-2:30)

AlNoor University College
Pharmacy Department
1st Course/ 4th Class
2023/2024
Use of steric shields

Design of cholinergic agonists

Rationale

Shields protect ester from nucleophiles and enzymes

Shield size is important

Must be large enough to hinder hydrolysis

Must be small enough to fit binding site

Requirements

Correct size

Correct pharmacophore - ester and quaternary nitrogen

Increased stability to acid and esterases

Increased selectivity
Pharmacologic manipulation of the cholinergic system

Action Potential

Na⁺

Presynaptic neuron

Acetyl CoA + Choline → Acetylcholine

Choline Acetyltransferase

H⁺

Ca²⁺

Acetylcholinesterase

Muscarinic Receptor

Nicotinic Receptor

Postsynaptic target

Choline Acetate
Cholinomimetics = parasympathomamitcs

- **Direct Acting**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>STRUCTURE</th>
<th>CLASS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholine</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>Choline esters</td>
</tr>
<tr>
<td>Carbachol</td>
<td><img src="image2.png" alt="Structure" /></td>
<td>Choline esters</td>
</tr>
<tr>
<td>Bethanechol</td>
<td><img src="image3.png" alt="Structure" /></td>
<td>Choline esters</td>
</tr>
<tr>
<td>Methacholine</td>
<td><img src="image4.png" alt="Structure" /></td>
<td>Choline esters</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td><img src="image5.png" alt="Structure" /></td>
<td>Alkaloid derivative</td>
</tr>
</tbody>
</table>

![Diagram](image6.png)
Design of cholinergic agonists (DIRECT)

Properties
Three times more stable than acetylcholine
Increasing the shield size increases stability but decreases activity
Selective for muscarinic receptors over nicotinic receptors
S-enantiomer is more active than the R-enantiomer
Stereochemistry matches muscarine
Not used clinically
Indirect Cholinergic Drugs

Cholinergic Drugs – Indirect acting

- **Cholinesterase inhibitors** or **reversible anticholinesterases**:
  1. **Natural**: Physostigmine
  2. **Synthetic**: Neostigmine, Pyridostigmine, Distigmine, Rivastigmine, Donepezil, Gallantamine, Edrophonium, Ambenonium, Demecarium

1. **Irreversible anticholinesterases**:
   1. **Organophosphorous Compounds (OPC)** – Diisopropyl fluorophosphate (DFP), Ectoiothophate, Parathion, malathion, diazinon (insecticides and pesticides)
   2. **Tabun, sarin, soman** (**nerve gases in war**)
   3. **Carbamate Esters**: Carbaryl and Propoxur (Baygon)
ANTICHOLINESTERASES AGENTS

Reversible:

**Short**
*Edrophonium*

**Medium**
*Neostigmine, Physostigmine, Pyridostigmine, Tacrine*
ANTI-CHOLINESTERASES AGENTS

Mechanism of action:
Acetyl cholinesterase (AchE) is an enzyme with anionic and esteratic site.

Acetylcholine (Ach) involves attraction of the positive charge N⁺ of Ach and anionic site; acetylation of serine leading to the acetylated enzyme.

The acetylated enzyme reacts with the water to produce acetic acid and free enzyme within milliseconds.
Pharmacologic manipulation of AChE: No inhibition
Pharmacologic manipulation of AChE: Inhibition by drugs

Presynaptic neuron

Action Potential

Na$^+$

Postsynaptic target

Muscarinic Receptor

Acetylcholinesterase

ACH

ACH

ACH

ACH

ACH

ACH

ACH

ACH

ACH

ACH

ACH

ACH
Acetylcholinesterase inhibitors

Most basic Nitrogen; protonated at physiological pH.

Edrophonium, Neostigmine and Physostigmine

They combine with the ChE and carbamylated enzyme is slow to hydrolyze and free the enzyme (~30 mins).
Acetylcholinesterase inhibitors

[Structure of Acetylcholinesterase inhibitor]

<table>
<thead>
<tr>
<th>R</th>
<th>Relative Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH₃</td>
<td>1.0</td>
</tr>
<tr>
<td>C₂H₅</td>
<td>5.0</td>
</tr>
<tr>
<td>C₃H₇</td>
<td>100</td>
</tr>
<tr>
<td>C₄H₉</td>
<td>50</td>
</tr>
</tbody>
</table>

- Quaternary ammonium alcohol
- Simplest structures
- Bind to anionic site and block ACh binding
- Reversible (Non-covalent)
Physostigmine is carbamylated at a slow rate and the carbamylated AChE also is regenerated quite slowly. Because physostigmine is a tertiary amine rather than a quaternary ammonium salt, it is more lipophilic than other AChEIs and can diffuse across the blood-brain barrier. It is investigated for use in the treatment of Alzheimer's disease.

- Sensitive to heat, light, moisture etc.
- Fully ionised (can't cross BBB)
- More stable to hydrolysis (extra N-methyl group increase stability)
- Antidote for Atropine poisoning
- Topical application of glaucoma
Neostigmine

- Chemically more stable than Neostigmine.
- Longer DoA
- Neostigmine administered orally or IV
- Prevent atony of intestinal, skeletal, and bladder musculature, also as urinary stimulant.
- Mostly used for treatment of MG

Pyridostigmine

- Pyridostigmine is a medication that treats myasthenia gravis (MG).
- Pyridostigmine (Mestinon) is slightly longer-acting (with a half-life of 4 hours) and has fewer cholinergic side effects than neostigmine bromide and other anticholinesterase preparations. Unlike physostigmine, pyridostigmine has no unwanted CNS effects because it does not cross the blood-brain barrier.
- HW??
- Compare among them?

Carbaryl

Widely used as insecticidal used on house plants and vegetables as well as for fleas and ticks on pets.
Acetylcholinesterase inhibitors

- Organophosphates
- Irreversible
- Covalent modification to AChE
- Longer acting
- Used in the treatment of glaucoma

- Organophosphates
- Nerve gases
- Irreversible
- Covalent modification to AChE

![ Isofluorophate; DFP (Floropryl) ]

![ Echothiophate (Phospholine Iodide) ]

![ Sarin ]

![ Soman ]
Acetylcholinesterase inhibitors

- Organophosphates
- Insecticides
- Irreversible
- Covalent modification to AChE
- Rapidly inactivated in mammals

Biotransformation of Insecticides

Malathion

Diazinon

Cyt P450

Insects

Carboxyesterase
Mammals, Birds

Malaoxon

Inactive
Antidote for AChE “poisoning”

- Pralidoxime Chloride (Protopam; 2-pyridine aldoxime methyl chloride; 2-PAM)
- Antidote for pesticide or nerve gas poisoning
- Most effective if given within a few hours of exposure
Irreversible Inhibitors

Compounds containing phosphoryl or phosphonic halides that can react with AChE to form AChE-phosphate complexes stable to hydrolytic cleavage.

Mainly used as agricultural insecticides and nerve gas agents.

Acetylcholinesterase (AChE)

AChE enzyme not regenerated
Synthesis of Ecothiophosphate

- Inhibits AChE irreversibly
- Long lasting inhibition (up to ~ 4 weeks)
- Applied topically to the eye in glaucoma treatment

Highly potent and irreversible AChE inhibitors
- Extremely toxic (nerve gas)

Synthesis of Ecothiophosphate
Pralidoxime Chloride (Protopam; 2-pyridine aldoxime methyl chloride; 2-PAM)

- Antidote for pesticide or nerve gas poisoning
- Most effective if given within a few hours of exposure
The phosphorylated ChE reacts very slowly or not at all with the water. If more OH groups in the form of Oximes are provided, reactivation occurs faster. Pralidoxime (PAM) attaches to the anionic site in presence of Organophosphorus compounds and set the enzyme free. PAM is ineffective in case of physostigmine poisoning as anionic site is not free.

**Organophosphate Aging – chemical stabilization of phosphate bond to AChE occurs over time**

Organophosphate has attached to AChE but bonding has not aged

![Organophosphate](image)

The rate of aging is unique for each organophosphate compound, and can occur over minutes to days depending on the agent

Organophosphate interaction has aged (AChE can’t be regenerated)

![Organophosphate Interaction](image)

The departure of the $R_2$ alkyl group (aging) results in increased electron sharing between the phosphate group of the organophosphate & the serine on AChE. This bond can’t be broken by 2-PAM.

**Pralidoxime (2-PAM) prevents aging & regenerates AChE**

2-PAM bonds to organophosphate bond to AChE is broken

![2-PAM Action](image)

“Regenerated AChE”
Treatment of Alzheimer’s Disease

Tacrine (Cognex)

nowadays there are not specific studies justifying why the protonation of the cationic species takes place on the central ring of the N atom while the Cl atom is bonded to the N of NH₂ in the HCl species instead ...

Donzepil (Aricept)

- Bind to anionic site and block ACh binding
- Reversible
- Non-covalent
- Enhances cognitive ability
- Does not slow progression of disease
- Newer agent: Donepezil (Aricept)
Treatment of Alzheimer’s Disease

Reversible carbamate AChE inhibitor
Enhances cognitive ability by increasing cholinergic function
Loses effectiveness as disease progresses
Side Effects: Nausea, vomiting, anorexia, and weight loss
Newer long-acting carbamate: Eptastigmine
Treatment of Alzheimer’s Disease

- Reversible competitive AChE inhibitor
- Extract from daffodil (Narcissus pseudonarcissus) bulbs
- Loses effectiveness as disease progresses
- May be a nicotinic receptor agonist
- Inhibitors of P450 enzymes (3A4, 2D6) will increase galantamine bioavailability
Treatment of Alzheimer’s Disease

- \(N\)-methyl-D-aspartate (NMDA) receptor antagonist
- NMDA receptors are activated by glutamate in the CNS in areas associated with cognition and memory
- Neuronal loss in Alzheimer’s may be related to increased activity of glutamate
- May slow progression of the disease
- Favorable adverse effect profile

Memantine (Namenda) addresses dysfunction in glutamatergic transmission, while the AChEIs serve to increase pathologically lowered levels of the neurotransmitter acetylcholine.
Cholinergic Antagonists

Lecture Outlines

- Introduction
- Muscarinic antagonists
  - Therapeutic application
  - Structure Activity Relationship (SAR) studies
  - Specific muscarinic antagonists
- Nicotinic antagonists
  - Introduction
  - Discovery
  - Different classes of nicotinic antagonists

Learning Objectives

After completion of this topic students should be able to

1. Identify the structures and discuss therapeutic uses of various classes muscarinic and nicotinic antagonists
2. Identify acetylcholine binding residues at the muscarinic receptor
3. Discuss structure activity/pharmacokinetic relationships of antimuscarinics including
   1. Substitution at alpha carbon with respect to ester group
   2. Substitution on the nitrogen
4. Identify chemical class of any muscarinic antagonist
5. Identify the metabolites (active/inactive) of specific antimuscarinics
6. Identify the structural requirements of a compound to be a neuromuscular blocker
7. Discuss how nicotinic antagonists bind at the receptor site
8. Compare and contrast depolarizing and non-depolarizing neuromuscular blockers
9. Identify the metabolites of (active and inactive) of steroid and tetrahydro isoquinoline type neuromuscular blockers
• Drugs which bind to cholinergic receptor but do not activate it
• Prevent acetylcholine from binding
• Opposite clinical effect to agonists - lower activity of acetylcholine

Muscarinic antagonists are commonly referred to as

- Anticholinergics
- Antimuscarinics
- Cholinergic blockers
- Antispasmodics
- Parasypatholytics

Clinical Effects
- Decrease of saliva and gastric secretions
- Relaxation of smooth muscle
- Decrease in motility of GIT and urinary tract
- Dilation of pupils

Uses
- Shutting down digestion for surgery
- Ophthalmic examinations
- Relief of peptic ulcers
- Treatment of Parkinson’s Disease
- Anticholinesterase poisoning
- Motion sickness
What are the therapeutic applications of antimuscarinics?

<table>
<thead>
<tr>
<th>Organ</th>
<th>M-Receptor Effect</th>
<th>Antimuscarinic effect</th>
<th>Therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iris circular muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td></td>
</tr>
<tr>
<td>Ciliary muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td>Mydriatic</td>
</tr>
<tr>
<td>Heart</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinoatrial node</td>
<td>Decelerates</td>
<td>Accelerates</td>
<td>Bradycardia</td>
</tr>
<tr>
<td>Atrial contractility</td>
<td>Decelerates</td>
<td>Accelerates</td>
<td>Bradycardia</td>
</tr>
<tr>
<td>Bronchiole smooth muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td>Asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smooth muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td>GI antispasmodic</td>
</tr>
<tr>
<td>Secretions</td>
<td>Increases</td>
<td>Decreases</td>
<td></td>
</tr>
<tr>
<td>Sphincters</td>
<td>Relaxes</td>
<td>Contracts</td>
<td>Overactive bladder</td>
</tr>
<tr>
<td>Bladder smooth muscles</td>
<td>Contracts</td>
<td>Relaxes</td>
<td></td>
</tr>
</tbody>
</table>
Muscarinic Antagonists

Binding Site (Muscarinic)

It is postulated that muscarinic antagonists bind to the Asp and contain hydrophobic substituents that bind to a hydrophobic pocket in the receptor, which does not allow the change in conformation needed to transfer the agonist signal to the coupled G protein.
Structural Activity Relationship

Ach

Acetyl CH3 group is substituted with at least one phenyl ring for antimuscarinic activity

Ach Muscarinic Antagonists
Organic Pharm. Chemistry II

Lecture 3
7th October 2023 (8:30-11:30) (11:30-2:30)

AlNoor University College
Pharmacy Department
1st Course/ 4th Class
2023/2024
Anticholinergic

- Introduction
- Muscarinic antagonists
  - Therapeutic application
  - Structure Activity Relationship (SAR) studies
  - Specific muscarinic antagonists
- Nicotinic antagonists
  - Introduction
  - Discovery
  - Different classes of nicotinic antagonists
Learning objectives

After completion of this topic students should be able to

1. Identify the structures and discuss therapeutic uses of various classes muscarinic and nicotinic antagonists
2. Identify acetylcholine binding residues at the muscarinic receptor
3. Discuss structure activity/pharmacokinetic relationships of antimuscarinics including
   1. Substitution at alpha carbon with respect to ester group
   2. Substitution on the nitrogen
4. Identify chemical class of any muscarinic antagonist
5. Identify the metabolites (active/inactive) of specific antimuscarinics
6. Identify the structural requirements of a compound to be a neuromuscular blocker
7. Discuss how nicotinic antagonists bind at the receptor site
8. Compare and contrast depolarizing and non-depolarizing neuromuscular blockers
9. Identify the metabolites of (active and inactive) of steroid and tetrahydro isoquinoline type neuromuscular blockers
What is muscarinic antagonist

- An agent that have high binding affinity for the muscarinic receptor but have no intrinsic activity.

What are they competing with to occupy muscarinic receptor?

- Acetylcholine
- They are competitive (reversible) antagonists of acetylcholine
- Their pharmacological actions are opposite to that of the muscarinic agonists
Muscarinic Antagonists

- Drugs which bind to cholinergic receptor but do not activate it
- Prevent acetylcholine from binding
- Opposite clinical effect to agonists - lower activity of acetylcholine
Muscarnic Antagonists

Clinical Effects
- Decrease of saliva and gastric secretions
- Relaxation of smooth muscle
- Decrease in motility of GIT and urinary tract
- Dilation of pupils

Uses
- Shutting down digestion for surgery
- Ophthalmic examinations
- Relief of peptic ulcers
- Treatment of Parkinson’s Disease
- Anticholinesterase poisoning
- Motion sickness
Muscarnic antagonists are commonly referred to as

- Anticholinergics
- Antimuscarinics
- Cholinergic blockers
- Antispasmodics
- Parasypatholytics
### What are the therapeutic applications of antimuscarinics?

<table>
<thead>
<tr>
<th>Organ</th>
<th>M-Receptor Effect</th>
<th>Antimuscarinic effect</th>
<th>Therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eye</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iris circular muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td></td>
</tr>
<tr>
<td>Ciliary muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td>Mydriatic</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinoatrial node</td>
<td>Decelerates</td>
<td>Accelerates</td>
<td>Bradycardia</td>
</tr>
<tr>
<td>Atrial contractility</td>
<td>Decelerates</td>
<td>Accelerates</td>
<td>Bradycardia</td>
</tr>
<tr>
<td><strong>Bronchiole smooth muscle</strong></td>
<td>Contracts</td>
<td>Relaxes</td>
<td>Asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td><strong>Gastrointestinal tract</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smooth muscle</td>
<td>Contracts</td>
<td>Relaxes</td>
<td>GI antispasmodic</td>
</tr>
<tr>
<td>Secretions</td>
<td>Increases</td>
<td>Decreases</td>
<td></td>
</tr>
<tr>
<td>Sphincters</td>
<td>Relaxes</td>
<td>Contracts</td>
<td>Overactive bladder</td>
</tr>
<tr>
<td>Bladder smooth muscles</td>
<td>Contracts</td>
<td>Relaxes</td>
<td></td>
</tr>
</tbody>
</table>
Binding site (muscarinic)
Binding site (muscarinic)

It is postulated that muscarinic antagonists bind to the Asp and contain hydrophobic substituents that bind to a hydrophobic pocket in the receptor, which does not allow the change in conformation needed to transfer the agonist signal to the coupled G protein.
Structure Activity Relationship (SAR) Studies

Acetyl CH3 group is substituted with at least one phenyl ring for antimuscarinic activity

Acetylcholine (ACH)

Acetylcholine analogue antimuscarinics
Substitutions at α-carbon with respect to ester group

1. May be a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or a carboxamide
2. Hydroxyl group or a hydroxymethyl group, the antagonist usually is more potent

$R_2$ and $R_3$ should be carbocyclic or heterocyclic rings (phenyl, cyclohexyl, cyclopentyl) for maximal antagonist potency

Substitution of naphthalene rings at $R_2$ and $R_3$ affords inactive compounds, because of steric hindrance at the muscarinic receptor.

Bigger $R_2$ and $R_3$ groups bind to the hydrophobic region outside the Ach receptor site

The hydroxyl group at $R_1$ presumably increases binding strength by participating in a hydrogen bond interaction at the receptor.
What about cholinomimetic? Please compare??
Substitution at the amine group

Compounds possessing the quaternary ammonium group exhibit nicotinic antagonist activity at high doses.

Quaternary ammonium compounds possess most potent anticholinergic activity

Methyl, ethyl, propyl, or isopropyl groups are tolerated

Tertiary amines also possess antagonist activity, presumably by binding to the receptor in the protonated form.

Quaternary ammonium drugs are primarily used in the treatment of ulcers or other conditions for which a reduction in gastric secretions and reduced motility of the gastrointestinal tract are desired.
Changes at $R_4$ position

Optimum chain length is 2-4 carbons. Two carbon chain possess the most antagonistic activity.
The Pharmacophore for all classes of antimuscarinics

Acetylcholine (ACH)

\[ R_1 = \text{OH} : \text{Aminoalcohol ester} \]
\[ R_1 = \text{CONH}_2 : \text{Aminoamide ester} \]

\[ R_1 = \text{OH} : \text{Aminoalcohol} \]
\[ R_1 = \text{CONH}_2 : \text{Aminoamides} \]

\[ R_1 = \text{OH} : \text{Aminoalcohol ether} \]
\[ R_1 = \text{CONH}_2 : \text{Aminoamide ether} \]

Acetylcholine analogue antimuscarinics
Identify which chemical class the following compounds belong to ...

Glycopyrrolate
(Nodapton, Robinal, Tarodyl)

Propantheline
(Corrigast, Pro-Banthine, Pantheline)

Clidinium
(Quarzan)

Flavoxate
(Bladderon, Spasuret, Urispas)

Oxyphencyclimine
(Antulcus, Setrol, Daricon)

Ipratropium
(Atem, Atrovent, Narilet)
More Drugs...

Trospium Chloride (Sanctura)

Procyclidine (Kemadrin)

Trihexyphenidyl (Artane)

Urinary and GI antispasmodic

Antiparkinsonism

Antiparkinsonism

Benztropine (Cogentin)

Orphenadrine (Norflex)

Tolterodine (Detrol)

Antiparkinsonism

Muscle relaxant (skeletal); antihistaminic

Urinary incontinence
Muscarinic receptor subtype selectivity

- With the exception of solifenacin and darifenacin (selective M₃ antagonists), all other agents discussed in this chapter display no marked selectivity for muscarinic receptor subtypes.
SPECIFIC
ANTIMUSCARINIC
DRUGS
Atropine: Classic Prototype for Antimuscarinics

- Amino alcohol ester pharmacophore

- Quaternary Nitrogen binds to the anionic Asp residue in the muscarinic receptor

- When the Nitrogen made is quaternary, molecule loses oral availability, but effective by inhalation

- Methyl is optimal substitution on Quaternary Nitrogen

- R-isomer is 100 fold more active than and S-isomer

- There is little difference between R- and S-configurations

- The naturally occurring alkaloid, (-)-hyoscyamine, upon base-catalyzed racemization gives (±)-hyoscyamine or atropine.

- **Uses**: antidote for anticholine esterase poisoning, Decrease GIT motility, Dilation of pupils
Scopalamine (Hyoscine)

- Chemically and pharmacologically similar to atropine
- CNS depressant where as other antimuscarinics are CNS stimulants
- Used in the treatment of motion sickness, parkinsonism
- Used as a truth drug (CNS effects)
Antimuscarinic drugs used in the treatment of urinary incontinence

1. Tolterodine
2. Oxybutynin
3. Solifenacin
4. Darifenacin
Tolterodine (Detrol®)

- Oxidation to hydroxymethyl Tolterodine (Active)
- Further oxidation to Carboxylic acid

Non-selective muscarinic antagonist

Metabolites:
1. 5-hydroxymethyl (Active)
2. N-dealkylated-5-carboxylic acid

Acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective.

Known Side Effects:
- Hyposalivation (Dry mouth)
- Decreased gastric motility (Upset stomach)
- Headache, Constipation, Dry eyes, Drowsiness

Half Life: 2-4 hrs
Oxybutynin (Ditropan®)

The (R)-enantiomer is a more potent anticholinergic than the (S)-enantiomer, but marketed as racemic mixture.

Half Life: 2-5 hrs
Solifenacin (Vescicare)

Half Life: 55 hrs

Metabolites:
1. 4-hydroxy derivative (active),
2. N-glucuronide
3. N-oxide
4. 4-hydroxy-N-oxide

Selective M3 antagonist

Solifenacin
Vescicare 5 mg, 10 mg
Darifenacin (Enablex®)

Selective M3 antagonist

CYP3A4  CYP2D6

N-dealkylation

Hydroxylation
Antimuscarinic drugs used in the treatment of bronchial asthma

- Ipratropium hydrobromide
- Tiotropium bromide

**$M_3$ receptors:** Bronchiole constriction

**Therapeutic use:** block cholinergic bronchiole constriction (anticholinergics) and allow adrenergic bronchiole dilation to help overcome the pulmonary constriction associated with asthmatic attack.
Ipratropium Hydrobromide (Atrovent®)

- N-isopropyl analogue of Atropine

- Quaternary cationic nature makes it highly hydrophilic and poorly absorbed from the lungs after inhalation via solution or aerosol, so bronchodilation effect can be considered to be a local, site-specific effect

- Ipratropium is indicated primarily for the relief of bronchospasms associated with COPD and has seen little application for the treatment of asthma

- Reaches the circulation minimally and is partially metabolized to inactive esterase products
Tiotropium Bromide (Spiriva®)

- Dithienyl derivative of N-methyl scopolamine, a quaternary analogue of naturally occurring scopolamine in Atropa belladonna
- Indicated primarily for the relief of bronchospasms associated with COPD and can be considered to be a site-specific, local medication to the lung.
- Longer duration of action than ipratropium (24 versus <4 hours, respectively).
- Tiotropium is metabolized by both CYP3A4 and CYP2D6, followed by glutathione conjugation to a variety of metabolites.
Cholinergics

Cholinergic drugs
- Nicotinic
- Muscarinic

Agonists
- Nicotinic
- Muscarinic

Antagonists
- Nicotinic antagonists as neuromuscular blockers

Acetylcholine at the nicotinic receptor site
- Anionic binding pocket
Nicotinic Antagonists

- Compounds that bind to cholinergic nicotinic receptors with no intrinsic efficacy (competitive antagonists with Ach)

- Two subclasses of nicotinic antagonists
  - Skeletal neuromuscular blocking agents and
  - Ganglionic blocking agents.

- DONOT confuse with skeletal muscle relaxants that produce their effects through the CNS
Events and sites of drug action at a nicotinic cholinergic synapse

Neuromuscular Blockers

Resource: Rang and Dale's Pharmacology, 6th Edition, Chapter 10, Fig. 10.2
Depolarizing blockers: Depolarizes the post synaptic membrane with the inflow of sodium ions
Non-depolarizing blockers: Blocks the sodium ions conductance
Therapeutic application

- Neuromuscular blocking agents are used primarily as an adjunct to general anesthesia.
  - Produces skeletal muscle relaxation which facilitates operative procedures

Questions to be considered in choosing NMB
1. Will the compound produce the desired neuromuscular blockade?
2. What is its duration of action?
3. What are its adverse effects?
4. What is its relative cost?
Discovery: Tubocurarine – the first neuromuscular blocker

- The neuromuscular blocking effects of extracts of curare were first reported as early as 1510

- It was demonstrated that curare extracts prevented skeletal muscle contractions by an effect at the neuromuscular junction
Tubocurarine structure

Incorrect structure: 1935

- Nevertheless, the incorrect structure of tubocurarine served as the model for the synthesis of all the neuromuscular blocking agents in use today
Rationale for designing new compounds

- Bis-quaternary ammonium compound having two quaternary ammonium salts separated by 10 to 12 carbon atoms (similar to the distance between the nitrogen atoms in tubocurarine) was a requirement for neuromuscular blocking activity.

- The rationale for this structural requirement was that nicotinic receptors possessed two anionic-binding sites, both of which had to be occupied for a neuromuscular blocking effect.

- Nicotinic antagonist may be a
  - Depolarizing neuromuscular blocker
  - Non-depolarizing neuromuscular blocker
Depolarizing agents

- Decamethonium Bromide
- Succinylcholine Chloride (Anectine®)
Decamethonium Bromide

10 carbon bridge between two nitrogens

Bis-quaternary ammonium salt

Decamethonium at the nicotinic receptor
Acetylcholine at the nicotinic receptor site

Anionic binding pocket

Anionic binding pocket
Succinyl choline

- Dimer of acetylcholine bonded through their α-carbon adjacent to ester
- Rapidly hydrolyzed to inactive metabolites, both in aqueous solution and plasma esterases (shorter duration of action, 6-8 min)
- Through succinylcholine has 10 atoms between two nitrogens, it still reported to catalyze with two molecules at the receptor site.
Non-depolarizing agents

Aminosteroids
- Pancuronium bromide (Pavulon)
- Vecuronium bromide (Norcuron)
- Rocuronium bromide (Zemuron)
- Pipecuronium bromide (Arduan)

Tetrahydroisoquinolines
- d-Tubocurarine and metocurine (Metubine Iodide)
- Atracurium besylate (Tracrium)
- Cis-atracurium
- Mivacurium chloride (Mivacron)
- Doxacurium chloride (Nuromax)
Monoquaternary aminosteroids are less potent but has faster onset of action
Vecuronium at the nicotinic receptor
**Vecuronium (Norcuron)**

- 17 deacetylated metabolite is active
- 3-deacetylated metabolite is active
- Metabolites:
  - 3-hydroxy metabolite (Active)
  - 17-hydroxy metabolite (Active)
  - 3, 17-dihydroxy metabolite (Active)

Accumulation is responsible for prolonged neuromuscular blockade in patients receiving long-term therapy.
Pancuronium Bromide (Pavulon)

3-deacetylated metabolite is active as long as 17 deacetylation does not occur

17 deacetylated metabolite is inactive

Metabolites:
3-hydroxy metabolite (Active)
17-hydroxy metabolite (Inactive)
3, 17-dihydroxy metabolite (Inactive)
Tetrahydroisoquinolines

**d-Tubocurarine and metocurine (Metubine Iodide®)**

- **d-Tubocurarine**
  - Long duration of action
  - Mostly eliminated unchanged via kidney and bile, <1% gets demethylated in the liver

- **Metocurine iodide**
  - Long duration of action
  - 4 fold more potent than d-tubocurarine
  - Eliminated unchanged via kidney
Tetrahydroisoquinolines

Hoffman Degredation (HD)

No HD
Atracurium metabolism

Hofmann elimination

Laudanosine (Inactive)

Mivacurium and Doxacurium do not undergo Hofmann elimination like atracurium

Ester hydrolysis

Quaternary ammonium alcohol

Quaternary ammonium carboxylic acid

Ester hydrolysis

Laudanosine
Structure Activity Relationships

- Contain at least one +ve charged quaternary amine (4 C atoms attached to nitrogen) like Ach
- \(N^+\) attracted to Alpha sub unit of AChR (-ve charge)
  
  *Bis quaternary amines*

- Succinylcholine, Pancuronium, Atracurium
  
  *Mono quaternary amines*

- D-Tubocurarine, Vecuronium, Rocuronium
- In acidosis, Tertiary amine protonated → + charge → increased potency
- Bridging structure in between two amines is lipophilic and determines potency
- 10-12 carbon bridge between two nitrogens is optimal for maximal neuromuscular blockade.
# Metabolism of neuromuscular blockers

<table>
<thead>
<tr>
<th>Agent</th>
<th>Duration of action (min)</th>
<th>Metabolites</th>
<th>Mode of elimination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Succinylcholine</td>
<td>6–8</td>
<td>Ester hydrolysis (inactive)</td>
<td>Hydrolysis by plasma cholinesterases</td>
</tr>
<tr>
<td>d-Tubocurarine</td>
<td>80–120</td>
<td>Mostly unchanged</td>
<td>Renal elimination, liver clearance</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>30–40</td>
<td>3-hydroxy, 17-hydroxy, 3,17-dihydroxy (all active)</td>
<td>Liver metabolism and clearance, renal elimination</td>
</tr>
<tr>
<td>Pancuronium</td>
<td>120–180</td>
<td>3-hydroxy (active) 17-hydroxy, 3,17-dihydroxy (inactive)</td>
<td>Renal elimination, liver metabolism and clearance</td>
</tr>
<tr>
<td>Pimecuronium</td>
<td>80–100</td>
<td>Primarily unchanged</td>
<td>Renal elimination, liver metabolism and clearance</td>
</tr>
<tr>
<td>Rocuronium</td>
<td>30–40</td>
<td>Primarily unchanged</td>
<td>Liver metabolism and clearance</td>
</tr>
<tr>
<td>Atracurium</td>
<td>30–40</td>
<td>Ester hydrolysis products, Laudanosine (all inactive)</td>
<td>Hofmann degradation, hydrolysis by plasma cholinesterases</td>
</tr>
<tr>
<td>Mivacurium</td>
<td>12–18</td>
<td>Ester hydrolysis products (inactive)</td>
<td>Hydrolysis by plasma cholinesterases</td>
</tr>
<tr>
<td>Doxacurium</td>
<td>90–120</td>
<td>Ester hydrolysis products (Inactive)</td>
<td>Renal elimination, liver metabolism</td>
</tr>
</tbody>
</table>

Duration of action: 0-29 min: Short acting; 30-40 min: Intermediate acting; over 40 min: long acting
QUESTIONS